

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrRETEVMO®

Selpercatinib capsules

For Oral use

40 mg, 80 mg of selpercatinib

Selpercatinib tablets

For Oral use

40 mg, 80 mg of selpercatinib

Protein Kinase Inhibitor

RETEVMO®, indicated as monotherapy for the treatment of:

- metastatic *RET* fusion-positive non-small cell lung cancer (NSCLC) in adult patients,
- *RET*-mutant medullary thyroid cancer in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease,
- *RET* fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.

has been issued market authorization with conditions, pending the results of trials to verify its clinical benefit. Patients should be advised of the nature of the authorization. For further information for RETEVMO® please refer to Health Canada's Notice of Compliance with conditions - drug products web site: <https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions.html>

Eli Lilly Canada Inc.
Exchange Tower
130 King Street West, Suite 900
P.O. Box 73
Toronto, Ontario
M5X 1B1
1-888-545-5972
www.lilly.ca

Date of Authorization:
2026-02-18

Submission Control Number: 302404

RETEVMO is a registered trademark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates.

What is a Notice of Compliance with Conditions (NOC/c)?

An NOC/c is a form of market approval granted to a product on the basis of promising evidence of clinical effectiveness following review of the submission by Health Canada.

Products authorized under Health Canada's NOC/c policy are intended for the treatment, prevention or diagnosis of a serious, life-threatening or severely debilitating illness. They have demonstrated promising benefit, are of high quality and possess an acceptable safety profile based on a benefit/risk assessment. In addition, they either respond to a serious unmet medical need in Canada or have demonstrated a significant improvement in the benefit/risk profile over existing therapies. Health Canada has provided access to this product on the condition that sponsors carry out additional clinical trials to verify the anticipated benefit within an agreed upon time frame.

Recent Major Label Changes

1 Indications	2025/07
1 Indications , 1.2 Geriatrics	2024/10
4 Dosage and Administration , 4.1 Dosing Considerations	2025/01
4 Dosage and Administration , 4.4 Administration	2026/02
6 Dosage Forms, Strengths, Composition and Packaging	2026/02
7 Warnings and Precautions , Carcinogenesis and Genotoxicity , Endocrine and Metabolism , Monitoring and Laboratory Tests , Respiratory , Reproductive Health	2025/01
7 Warnings and Precautions , Cardiovascular , Hepatic/Biliary/Pancreatic , Immune	2025/07
7 Warnings and Precautions , 7.1.3 Pediatrics (<18 years of age)	2024/06

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

Recent Major Label Changes	2
Part 1: Health Professional Information	5
1 Indications	5
1.1 Pediatrics.....	5
1.2 Geriatrics	5
2 Contraindications.....	5
3 Serious Warnings and Precautions Box	6
4 Dosage and Administration	6
4.1 Dosing Considerations	6
4.2 Recommended Dose and Dosage Adjustment	6
4.4 Administration.....	9
4.5 Missed Dose.....	9
5 Overdose.....	9
6 Dosage Forms, Strengths, Composition, and Packaging	10
7 Warnings and Precautions	10
Carcinogenesis and Genotoxicity.....	10
Cardiovascular	11
Driving and Operating Machinery.....	12
Endocrine and Metabolism.....	12
Hematologic	12
Hepatic/Biliary/Pancreatic	12
Immune	12
Impaired Wound Healing.....	12
Monitoring and Laboratory Tests	13
Reproductive Health.....	13
Respiratory	14
Tumor Lysis Syndrome	14
7.1 Special Populations	14
7.1.1 Pregnancy	14
7.1.2 Breastfeeding	14
7.1.3 Pediatrics (<18 years of age)	14
7.1.5 Patients with Hepatic Impairment.....	15

7.1.6	Patients with Renal Impairment.....	15
8	Adverse Reactions.....	15
8.1	Adverse Reaction Overview.....	15
8.2	Clinical Trial Adverse Reactions.....	16
8.3	Less Common Clinical Trial Adverse Reactions.....	24
8.4	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data	25
9	Drug Interactions	29
9.2	Drug Interactions Overview	29
9.4	Drug-Drug Interactions	29
9.5	Drug-Food Interactions.....	35
9.6	Drug-Herb Interactions	36
9.7	Drug-Laboratory Test Interactions.....	36
10	Clinical Pharmacology.....	36
10.1	Mechanism of Action	36
10.2	Pharmacodynamics	36
10.3	Pharmacokinetics	37
11	Storage, Stability and Disposal	39
12	Special Handling Instructions.....	39
Part 2: Scientific Information		40
13	Pharmaceutical Information	40
14.	Clinical Trials.....	40
14.1	Clinical Trials by Indication	40
	Metastatic <i>RET</i> Fusion-Positive Non-Small Cell Lung Cancer.....	40
	<i>RET</i> -Mutant Medullary Thyroid Cancer.....	46
	<i>RET</i> Fusion-Positive Thyroid Cancer	52
14.2	Comparative Bioavailability Studies of the Product Monograph.....	53
15	Microbiology.....	54
16	Non-Clinical Toxicology	54
Patient Medication Information		57

Part 1: Health Professional Information

1 Indications

RETEVMO (selpercatinib) is indicated as monotherapy for the treatment of:

- metastatic *RET* fusion-positive non-small cell lung cancer (NSCLC) in adult patients,
- *RET*-mutant medullary thyroid cancer (MTC) in adult and pediatric patients 12 years of age and older with unresectable advanced or metastatic disease,
- *RET* fusion-positive differentiated thyroid carcinoma in adult patients with advanced or metastatic disease (not amenable to surgery or radioactive iodine therapy) following prior treatment with sorafenib and/or lenvatinib.

Treatment with RETEVMO should only be initiated following confirmation of a *RET* gene fusion or mutation using a validated test (see [14 Clinical Trials](#)).

Promising clinical effectiveness of RETEVMO for the above indications is based on objective response rates (ORR) and duration of responses (DOR) from LIBRETTO-001, a multi-center, multi-cohort, open-label, Phase 1/2 trial in patients with specific genetic alterations in *RET*. Further clinical information with regards to progression-free survival (PFS) were available from LIBRETTO-431 and LIBRETTO-531, multicentre, randomized, open-label Phase 3 trials for patients with NSCLC or MTC (see [14 Clinical Trials](#)).

1.1 Pediatrics

Pediatrics (12-17 years of age): Based on the data submitted and reviewed by Health Canada, the promising clinical effectiveness of RETEVMO have been established in adolescent patients 12-17 years of age with unresectable advanced or metastatic *RET*-mutant medullary thyroid cancer (see [7.1.3 Pediatrics \[<18 years of age\]](#)).

Pediatrics (<12 years of age): The safety and efficacy of RETEVMO in pediatric patients younger than 12 years of age have not been established (see [7.1.3 Pediatrics \[<18 years of age\]](#)).

1.2 Geriatrics

Geriatrics (≥65 years of age) Of the 837 patients in the safety database who received RETEVMO in LIBRETTO-001, 34% (287 patients) were ≥65 years of age and 10% (80 patients) were ≥75 years of age. No overall differences were observed in the safety or effectiveness of RETEVMO between patients who were ≥65 years of age and younger patients.

2 Contraindications

RETEVMO is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container. For a complete listing, see [6 Dosage Forms, Strengths, Composition and Packaging](#).

3 Serious Warnings and Precautions Box

Serious Warnings and Precautions

- Embryo-Fetal toxicity (see [7 Warnings and Precautions, Pregnancy](#))
- Hemorrhage (see [7 Warnings and Precautions, Hematologic](#))
- Hepatotoxicity (see [7 Warnings and Precautions, Hepatic/Biliary/Pancreatic](#))
- Hypersensitivity (see [7 Warnings and Precautions, Immune](#))
- Hypertension (see [7 Warnings and Precautions, Hypertension](#))
- Interstitial Lung Disease (ILD)/Pneumonitis (see [7 Warnings and Precautions, Respiratory](#))
- QTc interval prolongation (see [7 Warnings and Precautions, Cardiovascular](#) and [10.2 Pharmacodynamics, Cardiac Electrophysiology](#))

RETEVMO should only be prescribed and supervised by a qualified health professional experienced in the use of anti-cancer agents.

4 Dosage and Administration

4.1 Dosing Considerations

- Confirm the presence of a *RET* gene fusion (for patients with NSCLC or thyroid cancer) or a *RET* gene mutation (for patients with MTC) using a validated test before starting treatment with RETEVMO.
- Patient blood pressure is to be optimized before starting RETEVMO.
- Reduce RETEVMO dose in patients with severe hepatic impairment (see [4.2 Recommended Dose and Dosage Adjustment](#)).
- Assess QT interval and serum electrolytes at baseline and periodically during treatment (see [7 Warnings and Precautions](#)).

4.2 Recommended Dose and Dosage Adjustment

The recommended dosage of RETEVMO is based on body weight:

- Less than 50 kg: 120 mg twice daily
- 50 kg or greater: 160 mg twice daily

RETEVMO is administered orally approximately every 12 hours until disease progression or unacceptable toxicity.

Patients with severe hepatic impairment (Child-Pugh C) (less than 50 kg or 50 kg or greater) should receive a reduced dose of 80 mg twice daily (see [10.3 Pharmacokinetics, Special Populations and Conditions](#)) and monitor ALT and AST more frequently as clinically indicated.

Health Canada has not authorized an indication for use in children <12 years of age (see [1 Indications](#)).

Dosage Modifications for Adverse Reactions

Table 1 provides dose modifications for QT interval prolongation, increased aspartate aminotransferase (AST) or alanine aminotransferase (ALT), hypersensitivity, hypertension,

hemorrhagic events, interstitial lung disease/pneumonitis and other Grade 3 or 4 adverse reactions.

The RETEVMO dosage recommendations per dose reduction level, for the management of these adverse reactions, are provided in Table 2. Permanently discontinue RETEVMO in patients unable to tolerate the third dose reduction level.

Table 1 - Recommended RETEVMO Dosage Modifications for Adverse Reactions

Event	Grade*	Dose Modification
QT Interval Prolongation	Grade 3	<ul style="list-style-type: none"> Withhold RETEVMO until toxicity resolves to baseline or Grade 1. Resume RETEVMO at a reduced dose by 1 dose level. Permanently discontinue if QT prolongation remains uncontrolled after 2 dose reductions.
	Grade 4 or if patient has signs or symptoms of serious arrhythmia	<ul style="list-style-type: none"> Permanently discontinue RETEVMO.
AST/ALT Increase	Grade 3 and Grade 4	<ul style="list-style-type: none"> Withhold RETEVMO and perform AST/ALT monitoring once weekly until resolution to Grade 1 or baseline. Resume RETEVMO at a reduced dose by 2 dose levels and monitor AST/ALT once weekly. RETEVMO may be increased by 1 dose level after a minimum of 2 weeks without recurrence of increased AST/ALT. Increase to dose taken prior to the onset of Grade 3 or 4 ALT/AST increase after a minimum of 4 weeks without recurrence. Continue AST/ALT monitoring once weekly for 4 weeks thereafter. Permanently discontinue RETEVMO if recurrence of \geqGrade 3 toxicity despite dose reductions.
Hypersensitivity	All Grades	<ul style="list-style-type: none"> Hold RETEVMO until toxicity resolves and begin steroid treatment. Upon resolution of the event, resume RETEVMO at a reduced dose by 3 dose levels while continuing steroid treatment. If after 1 week RETEVMO is tolerated without recurrent hypersensitivity, increase RETEVMO by 1 dose level weekly, ensuring that RETEVMO is tolerated for at least 1 week before proceeding to the next dose level.

Event	Grade*	Dose Modification
		<ul style="list-style-type: none"> Taper steroid dose after RETEVMO has been tolerated for at least 7 days at the final dose. Permanently discontinue RETEVMO if recurrence of toxicity despite dose reductions.
Hypertension	Grade 3	<ul style="list-style-type: none"> Hold RETEVMO until hypertension is controlled with medical management. When controlled, resume RETEVMO at next lower dose level.
	Grade 4	<ul style="list-style-type: none"> Discontinue RETEVMO.
Hemorrhagic Events	Grade 3 or Grade 4	<ul style="list-style-type: none"> Withhold RETEVMO until recovery to baseline or Grade 0 or 1. Discontinue RETEVMO for severe or life-threatening hemorrhagic events.
ILD/Pneumonitis	Grade 2 that does not return to baseline or Grade 1 within 7 days despite maximal supportive measures	<ul style="list-style-type: none"> Withhold RETEVMO until toxicity resolves to baseline or Grade 1. Resume at next lower dose.
	Grade 3 or Grade 4	<ul style="list-style-type: none"> Discontinue RETEVMO.
Other Adverse Reactions	Grade 3 or Grade 4	<ul style="list-style-type: none"> Withhold RETEVMO until recovery to baseline or Grade 0 or 1. Resume at a reduced dose.

*Severity as defined by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).

Table 2 - Recommended RETEVMO Dosage per Dose Reduction Level for the Management of Adverse Reactions

Dose Reduction levels	Recommended RETEVMO Dosage	
	Patients Weighing Less Than 50 kg	Patients Weighing 50 kg or Greater
First	80 mg orally twice daily	120 mg orally twice daily
Second	40 mg orally twice daily	80 mg orally twice daily
Third	40 mg orally once daily	40 mg orally twice daily

Dosage Modifications for Concomitant Use of Strong or Moderate CYP3A4 Inhibitors

Avoid concomitant use of strong or moderate CYP3A4 inhibitors with RETEVMO. If concomitant use of a strong or moderate CYP3A4 inhibitor cannot be avoided, reduce the current RETEVMO dose as recommended in Table 3 and monitor the QTc interval more frequently with ECGs. After the inhibitor has been discontinued for 3 to 5 elimination half-lives of the inhibitor, resume RETEVMO at the dose taken before starting the CYP3A4 inhibitor (see [9.4 Drug-Drug Interactions](#) and [10.3 Pharmacokinetics](#)).

Table 3 - Recommended RETEVMO Dosage for Concomitant Use of Strong or Moderate CYP3A Inhibitors

Current RETEVMO Dosage	Recommended RETEVMO Dosage	
	With a Moderate CYP3A Inhibitor	With a Strong CYP3A Inhibitor
120 mg orally twice daily	80 mg orally twice daily	40 mg orally twice daily
160 mg orally twice daily	120 mg orally twice daily	80 mg orally twice daily

There is no data on the safety of concomitant use of CYP3A inhibitors in patients whose RETEVMO dose was previously reduced due to adverse reactions.

Dosage Modifications for Concomitant Use of Acid-Reducing Agents

Avoid concomitant use of a proton pump inhibitor, a histamine-2 (H₂) receptor antagonist, or a locally acting antacid with RETEVMO (see [9.4 Drug-Drug Interactions](#)). If concomitant use cannot be avoided,

- RETEVMO should be taken with food when co-administered with a proton pump inhibitor.
- RETEVMO should be taken 2 hours before or 10 hours after administration of an H₂ receptor antagonist.
- RETEVMO should be taken 2 hours before or 2 hours after administration of a locally acting antacid.

4.4 Administration

RETEVMO can be taken with or without food unless coadministered with a proton pump inhibitor (see [4.2 Recommended Dose and Dosage Adjustment](#)).

Patients should swallow the capsule or tablet whole. Do not crush or chew the capsule or tablet.

4.5 Missed Dose

If the patient misses a dose of RETEVMO, the patient should take the next dose at the next scheduled time, unless it is more than 6 hours until the next scheduled dose.

If the patient vomits after taking a dose of RETEVMO, the patient should not take an additional dose. The patient should take the next dose at the next scheduled time. The patient should not take 2 doses at the same time to make up for the missed dose.

5 Overdose

There is no known antidote for RETEVMO. The treatment of overdose of RETEVMO should consist of general supportive measures. ECG monitoring is recommended.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6 Dosage Forms, Strengths, Composition, and Packaging

Table 4 - RETEVMO Dosage Forms, Strengths, Composition

Route of Administration	Dosage Form / Strength/Composition	Non-medicinal Ingredients
Oral	capsule 40 mg, 80 mg	Black iron oxide, colloidal silicon dioxide, FD & C Blue No. 1 (80 mg capsule only), gelatin, microcrystalline cellulose, pharmaceutical grade printing ink, titanium dioxide
	tablet 40 mg, 80 mg	Croscarmellose Sodium, Hydroxypropyl Cellulose, Mannitol, Microcrystalline Cellulose, Sodium Stearyl Fumarate Film coating material contains ferrosoferric oxide, polyvinyl alcohol, polyethylene glycol, titanium dioxide, and talc. Additionally, the film coating of the 80 mg tablets contain ferric oxide.

Description

Capsules:

- The 40 mg capsules are grey opaque hard gelatin capsules (size 2) with black printing of “Lilly 3977” and “40 mg” on the body of the capsule. They are supplied in 75 mL bottles of 60 capsules.
- The 80 mg capsules are blue opaque hard gelatin capsules (size 0) with black printing of “Lilly 2980” and “80 mg” on the body of the capsule. They are supplied in 125 mL bottles of 60 capsules and 190 mL bottles of 120 capsules.

Tablets:

All tablet strengths are supplied in 75 mL bottles each containing 60 tablets.

- The 40 mg tablets are light grey, film coated, round tablets debossed with “5340” on one side and “Ret 40” on the other.
- The 80 mg tablets are dark red-purple, film coated, round tablets debossed with “6082” on one side and “Ret 80” on the other.

7 Warnings and Precautions

Please see [3 Serious Warnings and Precautions Box](#).

Carcinogenesis and Genotoxicity

In a 2-year study assessing carcinogenicity in rats, vaginal tumors were observed in 5% of female rats administered with a dose of 40 mg/kg of selpercatinib (approximately 1 times the clinical exposure by AUC at the 160 mg twice daily dose) (see [16 Non-Clinical Toxicology](#)).

Cardiovascular

QTc Interval Prolongation: RETEVMO causes concentration-dependent QTc interval prolongation (see [8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data](#)). QTc interval prolongation can lead to an increased risk of ventricular arrhythmias including torsade de pointes. The use of RETEVMO should be avoided in patients with conditions that may increase the risk of experiencing torsade de pointes.

Torsade de pointes is a polymorphic ventricular tachyarrhythmia. Generally, the risk of torsade de pointes increases with the magnitude of QTc prolongation produced by the drug. If sustained, torsade de pointes can progress to ventricular fibrillation and sudden cardiac death.

Risk factors for torsade de pointes in the general population include, but are not limited to, the following: female gender, age ≥ 65 years, baseline prolongation of the QTc interval, presence of genetic variants affecting cardiac ion channels or regulatory proteins (especially congenital long QT syndromes), family history of sudden cardiac death at < 50 years of age, cardiac disease (e.g., myocardial ischemia or infarction, congestive heart failure, cardiomyopathy, conduction system disease), history of arrhythmias, electrolyte disturbances (e.g., hypokalemia, hypomagnesemia, hypocalcemia), conditions leading to electrolyte disturbances (e.g., persistent vomiting, eating disorders), bradycardia, acute neurological events (e.g., intracranial or subarachnoid hemorrhage, stroke, intracranial trauma), diabetes mellitus, and autonomic neuropathy.

Combination use of RETEVMO with other drugs known to prolong the QTc interval and/or strong or moderate CYP3A inhibitors should be avoided, as this may lead to further prolongation of the QTc interval. Use caution if RETEVMO is administered in combination with agents known to cause bradycardia (e.g., beta-blockers, non-dihydropyridine calcium channel blockers, clonidine, and digoxin) or drugs that can decrease electrolytes (see [9 Drug Interactions](#)). Monitor the QTc interval more frequently in these patients (see [7 Warnings and Precautions, Monitoring and Laboratory Tests](#)).

Patients must have a QTcF interval of ≤ 470 ms and serum electrolytes within normal range before starting RETEVMO treatment. Perform electrocardiograms and measure serum electrolytes before starting RETEVMO treatment and during treatment. Treatment with RETEVMO should be avoided in patients with uncorrected hypokalemia, hypomagnesemia, or hypocalcemia (see [7 Warnings and Precautions, Monitoring and Laboratory Tests](#)).

Interruption and dose reduction or permanent discontinuation of RETEVMO may be required based on the severity of QTc interval prolongation (see [4.2 Recommended Dose and Dosage Adjustment](#)).

Hypertension: Hypertension occurred in 43% to 48% of patients treated with RETEVMO, including Grade 3 or 4 hypertension in 19% to 20% of patients (see [8 Adverse Reactions](#)). Hypertension was most commonly managed through concomitant anti-hypertension medications.

Patient blood pressure is to be optimized before starting RETEVMO. Monitor blood pressure during RETEVMO treatment. Based on the level of increased blood pressure, RETEVMO may require dose modification (see [4.2 Recommended Dose and Dosage Adjustment](#)). Permanently discontinue RETEVMO if medically significant hypertension cannot be controlled with antihypertensive therapy.

Driving and Operating Machinery

RETEVMO may influence the ability to drive and use machines. Patients should be advised to be cautious when driving or using machines in case they experience fatigue or dizziness during treatment with RETEVMO.

Endocrine and Metabolism

Hypothyroidism: Hypothyroidism occurred in 11% to 16% of patients treated with RETEVMO (see [8 Adverse Reactions](#)). New onset or worsening of hypothyroidism may occur with RETEVMO treatment. Monitor patients for hypothyroidism and treat as medically appropriate (see [7 Warnings and Precautions, Monitoring and Laboratory Tests](#)).

Hematologic

Serious, including fatal, hemorrhagic events can occur with RETEVMO. In the LIBRETTO-001 clinical study, Grade ≥ 3 hemorrhagic events occurred in 3.5% of patients treated with RETEVMO, including 4 (0.5%) patients with fatal hemorrhagic events, including two cases of cerebral hemorrhage and one case each of tracheostomy site hemorrhage, and hemoptysis.

Permanently discontinue RETEVMO in patients with severe or life-threatening hemorrhage.

Hepatic/Biliary/Pancreatic

Serious hepatic adverse reactions occurred in 2.5% to 4.2% of patients treated with RETEVMO (see [8 Adverse Reactions](#)). Increased AST occurred in 47% to 77% of patients, including Grade 3 or 4 events in 5% to 10% of patients. Increased ALT occurred in 53% to 81% of patients, including Grade 3 or 4 events in 12% to 21% of patients. The median time to first onset for increased AST was 4.7 to 9.5 weeks (range: 1 days to 4 years) and for increased ALT, it was 4.4 to 6.1 weeks (range: 1 days to 3.6 years).

Monitor ALT and AST before starting RETEVMO, every 2 weeks during the first 3 months of treatment, then monthly thereafter and as clinically indicated. Withhold, reduce dose, or permanently discontinue RETEVMO based on the severity of ALT/AST increase (see [4.2 Recommended Dose and Dosage Adjustment](#) and [8 Adverse Reactions](#)).

Immune

Hypersensitivity occurred in 0.5% to 5.7% of patients receiving RETEVMO, including Grade 3 hypersensitivity in 1.9% of patients. The median time to onset was 1.9 weeks (range: 5 days to 3.9 years). Signs and symptoms of hypersensitivity included fever, rash, and arthralgias or myalgias with concurrent decreased platelets or AST/ALT increase.

If hypersensitivity occurs, withhold RETEVMO until toxicity resolves and begin steroid treatment. Upon resolution of the event, resume RETEVMO at a reduced dose by 3 dose levels for 1 week. If tolerated without recurrent hypersensitivity, increase RETEVMO by 1 dose level weekly. Continue steroid treatment until the target dose is reached and then taper (see [4.2 Recommended Dose and Dosage Adjustment](#)). Permanently discontinue RETEVMO if toxicity recurs despite dose reductions.

Impaired Wound Healing

Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, RETEVMO has the potential to adversely affect wound healing.

Withhold RETEVMO for at least 7 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of RETEVMO after resolution of wound healing complications has not been established.

Monitoring and Laboratory Tests

Perform electrocardiograms and measure serum electrolytes before starting RETEVMO treatment. Ensure a QTcF interval of ≤ 470 ms before starting RETEVMO treatment. Hypokalemia, hypomagnesemia, and hypocalcemia should be corrected prior to initiation or continuation of RETEVMO treatment. Monitor electrocardiograms and serum electrolytes in all patients after 1 week of RETEVMO treatment, at least monthly for the first 6 months of RETEVMO treatment, and otherwise as clinically indicated. Monitor the QTc interval more frequently in patients who are at an increased risk of torsade de pointes (see [7 Warnings and Precautions, QTc Interval Prolongation](#)), and adolescent patients <50 kg (see [7.1.3 Pediatrics <18 years of age](#)). Monitor the QTc interval more frequently if RETEVMO is concomitantly administered with strong or moderate CYP3A inhibitors or drugs known to prolong the QTc interval (see [9.4 Drug-Drug Interactions](#)).

Control hypertension before starting RETEVMO. Monitor blood pressure after 1 week of starting therapy, monthly for 6 months, and as clinically indicated (see [4.1 Dosing Considerations](#)).

Monitor thyroid function before and during treatment with RETEVMO (see [7 Warnings and Precautions, hypothyroidism](#)).

Monitor ALT and AST before starting RETEVMO, every 2 weeks during the first 3 months of treatment, then monthly thereafter and as clinically indicated (see [4.2 Recommended Dose and Dosage Adjustment](#)).

Monitor growth plates in adolescent patients with open growth plates. Consider interrupting or discontinuing therapy based on the severity of any growth plate abnormalities and based on an individual risk-benefit assessment.

Monitor adolescent patients for symptoms indicative of Slipped Capital Femoral Epiphysis/Slipped Upper Femoral Epiphysis (SCFE/SUFE), such as complaints of hip/knee pain or onset of a limp, and treat as medically and surgically appropriate.

Reproductive Health

Women of childbearing potential must be advised to avoid becoming pregnant while receiving RETEVMO.

Advise females of reproductive potential to use highly effective contraception during treatment with RETEVMO and for at least 2 weeks after the last dose.

Verify negative pregnancy status in women of reproductive potential before starting RETEVMO.

Advise men with female partners with reproductive potential to use effective contraception during treatment and for at least 2 weeks after the last dose of RETEVMO (see [4.2 Recommended Dose and Dosage Adjustment](#) and [16 Non-Clinical Toxicology, Reproductive and Developmental Toxicology](#)).

Fertility: RETEVMO may impair fertility in men and women of reproductive potential (see [16 Non-Clinical Toxicology, Reproductive and Developmental Toxicology](#)).

Function: Advise men that the use of RETEVMO may be associated with erectile dysfunction. Medications used for erectile dysfunction may be sensitive CYP3A4 substrates and should be used with caution with RETEVMO (see [9.4 Drug-Drug Interactions](#)).

Respiratory

Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis can occur in patients treated with RETEVMO (see [8 Adverse Reactions](#)). Monitor patients for pulmonary symptoms indicative of ILD/pneumonitis and treat as medically appropriate.

Based on severity of ILD/pneumonitis, dose interruption or discontinuation of RETEVMO may be required (see [4.2 Recommended Dose and Dosage Adjustment](#)).

Tumor Lysis Syndrome

Patients treated with RETEVMO may be at risk of tumor lysis syndrome if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Closely monitor patients at risk, consider appropriate prophylaxis including hydration, and treat as clinically indicated.

7.1 Special Populations

7.1.1 Pregnancy

RETEVMO should not be used during pregnancy. Based on findings in animals and its mechanism of action, RETEVMO can cause fetal harm when administered to a pregnant woman. In an embryo-fetal development study in rats during organogenesis, selpercatinib was teratogenic and caused embryoletality and malformations at maternal exposures that were approximately equal to the exposure of the recommended human dose (AUC) (see [16 Non-Clinical Toxicology, Reproductive and Developmental Toxicology](#)).

7.1.2 Breastfeeding

There are no data on the presence of selpercatinib in human milk, effects of selpercatinib on the breastfed child, or the effects of selpercatinib on milk production. Because of the potential for serious adverse reactions in breastfed children, advise a nursing woman to discontinue breastfeeding during RETEVMO treatment and for at least 2 weeks after the last dose of RETEVMO.

7.1.3 Pediatrics (<18 years of age)

In the clinical studies, there were no adolescent patients with RET fusion-positive thyroid cancer and only 4 adolescent patients (12, 15, 16 and 17 years of age) with advanced or metastatic *RET*-mutant medullary thyroid cancer.

Slipped Capital Femoral Epiphysis/Slipped Upper Femoral Epiphysis (SCFE/SUFE) has been reported in adolescent patients receiving RETEVMO (see [8 Adverse Reactions](#)). Monitor adolescent patients for symptoms indicative of SCFE/SUFE such as complaints of hip/knee pain or an onset of a limp and treat as medically and surgically appropriate.

RETEVMO is associated with a potential risk for delayed growth. In non-clinical studies, animals showed signs of physeal hypertrophy and tooth dysplasia at doses resulting in exposures of approximately 3 times (for rats) and approximately 0.3 times (for minipigs) the human exposure at the 160 mg twice daily clinical dose. In juvenile rats, epiphyseal growth

plate changes were associated with decreased femur length and reductions in bone mineral density that were not reversible (see [16 Non-Clinical Toxicology](#)). These observations may be relevant to pediatric patients with open growth plates. Monitor growth plates in adolescent patients with open growth plates. Consider interrupting or discontinuing therapy based on the severity of any growth plate abnormalities and based on an individual risk-benefit assessment.

RETEVMO may impair fertility in adolescents of reproductive potential. (see [16 Non-Clinical Toxicology, Reproductive and Developmental Toxicology](#)).

The safety of long-term use of RETEVMO in adolescent patients has not been evaluated.

The safety and efficacy of RETEVMO in patients under the age of 12 has not been established.

Reduce the RETEVMO dose in adolescent patients <50 kg (see [4.2 Recommended Dose and Dosage Adjustment](#)) and monitor the QTc interval more frequently with ECGs.

7.1.5 Patients with Hepatic Impairment

Limited safety data are available for the use of RETEVMO in patients with severe hepatic impairment. Patients with severe hepatic impairment should receive a reduced dose of RETEVMO (see [4 Dosage and Administration](#)) and monitor ALT and AST more frequently as clinically indicated.

7.1.6 Patients with Renal Impairment

The use of RETEVMO in patients with end-stage renal disease is not recommended (see [10.3 Pharmacokinetics – Special Populations and Conditions](#)).

8 Adverse Reactions

8.1 Adverse Reaction Overview

The safety of RETEVMO has been assessed in a single-arm, Phase 1/2 study of patients with *RET* fusion-positive solid tumors and in two Phase 3 randomized, open-label studies of patients with *RET* fusion-positive NSCLC and MTC.

The most common adverse reactions reported in $\geq 25\%$ of patients in any study receiving RETEVMO were hypertension, edema, AST increased, ALT increased, diarrhea, dry mouth, fatigue, rash, abdominal pain, constipation, blood creatinine increased, headache, blood bilirubin increased, nausea, thrombocytopenia, vomiting, cough and dyspnea.

Serious adverse events occurred in 51% of patients who received RETEVMO in LIBRETTO-001, 35% in LIBRETTO-431, and 22% in LIBRETTO-531. The most common serious adverse events reported in any study were pleural effusion, pneumonia, dyspnea, hemorrhage, hyponatremia, abdominal pain, abnormal hepatic function, sepsis, diarrhea, pyrexia, hypertension, and urinary tract infection.

Deaths due to an adverse reaction occurred in 6% of patients who received RETEVMO in LIBRETTO-001, 4.4% in LIBRETTO-431, and 2% in LIBRETTO-531; fatal adverse reactions that occurred in >1 patient included respiratory failure, cardiac arrest, sepsis, pneumonia, hemorrhage, dyspnea, cardiac failure, general physical health deterioration, sudden death, and myocardial infarction.

Permanent discontinuation of RETEVMO due to an adverse reactions occurred in 10% of patients who received RETEVMO in LIBRETTO-001, 10% in LIBRETTO-431 and 5% in LIBRETTO-531. Adverse reactions resulting in permanent discontinuation of RETEVMO in $\geq 0.5\%$ of patients in any study included: increased ALT, myocardial infarction, fatigue, sudden

death, sepsis, increased AST, multiple organ dysfunction, edema, diabetic ketoacidosis, chronic kidney disease, retinopathy, COVID-19, somatic symptom disorder.

Dosage interruptions of RETEVMO due to an adverse reactions occurred in 68% of patients who received RETEVMO in LIBRETTO-001, 72% in LIBRETTO-431 and 56 % in LIBRETTO-531. The most current adverse reactions requiring dosage interruption of RETEVMO included: ALT increased, AST increased, diarrhea, hypertension, QT prolongation, COVID-19 and rash.

Dose reductions due to an adverse event occurred in 43% of patients who received RETEVMO in the LIBRETTO-001, 51% in LIBRETTO-431 and 39% in LIBRETTO-531. Adverse reactions requiring dosage reductions in >2% of patients in any study included: ALT increased, AST increased, fatigue, QT prolongation, diarrhea, drug hypersensitivity, ascites, hypertension and rash.

8.2 Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. The adverse reaction rates observed in the clinical trials, therefore, may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse reaction information from clinical trials may be useful for identifying and approximating rates of adverse drug reactions in real-world use.

LIBRETTO-001

The safety of RETEVMO has been assessed in 837 patients from an open-label, multi-center, multi-cohort, single-arm, phase 1/2 study (LIBRETTO-001). Most patients had metastatic *RET*-altered solid tumors, including *RET* fusion-positive non-small cell lung cancer (n=362); *RET*-mutant medullary thyroid cancer (n=324) and *RET* fusion-positive advanced thyroid cancer (n=66). RETEVMO was evaluated as a single agent at 160 mg orally twice daily. Ninety-six percent (96%) of patients received at least one dose of RETEVMO at the recommended dosage of 160 mg orally twice daily. Patients received RETEVMO for a median duration of 30.1 months (range: 0.1-66.8 months). The median age was 59 years (range: 15 to 92 years); 3 (0.4%) were pediatric patients less than 18 years of age; 51% were male; and 68% were White, 23% were Asian, 5% were Hispanic/Latino, and 3% were Black. ECOG performance status was 0-1 (95%) or 2 (5%). Patients with hepatic, renal or cardiac impairment (including prolonged QT syndrome) at baseline were not included in LIBRETTO-001.

Treatment-emergent adverse events reported in $\geq 10\%$ of patients treated with RETEVMO in LIBRETTO-001 are listed in Table 5.

Table 5 - Treatment-Emergent Adverse Events (TEAEs) Occurring in $\geq 10\%$ of Patients with Metastatic *RET*-Altered Solid Tumors Treated with RETEVMO in LIBRETTO-001

System Organ Class Preferred Term ^a	RETEVMO N=837	
	All Grades ^b n (%)	Grade 3 or 4 n (%)
Blood and Lymphatic Disorders		
Hemorrhage ^c	203 (24.3)	25 (3.0)
Thrombocytopenia	145 (17.3)	29 (3.5)
Leukopenia	126 (15.1)	13 (1.6)
Lymphopenia	122 (14.6)	49 (5.9)

System Organ Class Preferred Term ^a	RETEVMO N=837	
	All Grades ^b n (%)	Grade 3 or 4 n (%)
Anemia	119 (14.2)	28 (3.3)
Neutropenia	96 (11.5)	22 (2.6)
Endocrine Disorders		
Hypothyroidism ^d	136 (16.2)	0
Gastrointestinal Disorders		
Diarrhea ^e	423 (50.5)	49 (5.9)
Dry mouth ^f	366 (43.7)	0
Abdominal pain ^g	306 (36.6)	26 (3.1)
Constipation	295 (35.2)	7 (0.8)
Nausea	289 (34.5)	14 (1.7)
Vomiting ^h	226 (27.0)	20 (2.4)
Stomatitis ⁱ	146 (17.4)	3 (0.4)
Ascites	124 (14.8)	17 (2.0)
Gastroesophageal reflux disease	120 (14.3)	3 (0.4)
Abdominal distension	119 (14.2)	2 (0.2)
General Disorders and Administrative Site Conditions		
Edema ^j	433 (51.7)	9 (1.1)
Fatigue ^k	407 (48.6)	33 (3.9)
Pyrexia	158 (18.9)	2 (0.2)
Asthenia	94 (11.2)	11 (1.3)
Infections and Infestations		
Urinary tract infection ^l	169 (20.2)	19 (2.3)
Corona virus infection	118 (14.1)	9 (1.1)
Pneumonia ^m	110 (13.1)	53 (6.3)
Upper respiratory tract infection	102 (12.2)	4 (0.5)
Investigations		
AST increased	316 (37.8)	73 (8.7)
ALT increased	305 (36.4)	99 (11.8)
Blood creatinine increased ⁿ	253 (30.2)	20 (2.4)
ECG QT prolonged ^o	177 (21.1)	41 (4.9)
Blood alkaline phosphatase increased	128 (15.3)	21 (2.5)

System Organ Class Preferred Term ^a	RETEVMO N=837	
	All Grades ^b n (%)	Grade 3 or 4 n (%)
Blood bilirubin increased	100 (11.9)	13 (1.6)
Weight increased	98 (11.7)	19 (2.3)
Weight decreased	94 (11.2)	6 (0.7)
Metabolism and Nutrition Disorders		
Decreased appetite	185 (22.1)	7 (0.8)
Hypocalcemia	142 (17.0)	24 (2.9)
Hyponatremia	139 (16.6)	77 (9.2)
Hypoalbuminemia	121 (14.5)	9 (1.1)
Hypomagnesemia	117 (14.0)	3 (0.4)
Hyperkalemia	107 (12.8)	17 (2.0)
Hypokalemia	90 (10.8)	17 (2.0)
Hyperphosphatemia	89 (10.6)	0
Musculoskeletal and Connective Tissue Disorders		
Arthralgia	192 (22.9)	3 (0.4)
Back pain	187 (22.3)	17 (2.0)
Pain in extremity	114 (13.6)	3 (0.4)
Myalgia	111 (13.3)	3 (0.4)
Musculoskeletal pain	87 (10.4)	1 (0.1)
Nervous System Disorders		
Headache ^p	246 (29.4)	15 (1.8)
Dizziness ^q	178 (21.3)	3 (0.4)
Psychiatric Disorders		
Insomnia	137 (16.4)	0
Reproductive system and breast disorders		
Erectile dysfunction ^{r,s}	70 (16.4)	3 (0.7)
Respiratory, Thoracic, and Mediastinal Disorders		
Cough ^t	227 (27.1)	0
Dyspnea ^u	222 (26.5)	33 (3.9)
Pleural effusion	118 (14.1)	22 (2.6)
Dysphonia	96 (11.5)	1 (0.1)
Skin and Subcutaneous Tissue Disorders		
Rash ^v	315 (37.6)	6 (0.7)
Dry skin	136 (16.2)	0
Alopecia	87 (10.4)	0

System Organ Class Preferred Term ^a	RETEVMO N=837	
	All Grades ^b n (%)	Grade 3 or 4 n (%)
Vascular Disorders		
Hypertension ^w	360 (43.0)	167 (20)

^a Reported adverse event terms were coded using MedDRA (version 21.0).

^b The severity of TEAEs was graded based on the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 4.03.

^c Hemorrhage includes hemorrhage, epistaxis, hematuria, hemoptysis, contusion, rectal hemorrhage, vaginal hemorrhage, ecchymosis, hematochezia, petechiae, traumatic hematoma, anal hemorrhage, blood blister, blood urine present, cerebral hemorrhage, conjunctival hemorrhage, gastric hemorrhage, hemorrhage intracranial, hemorrhoidal hemorrhage, spontaneous hematoma, abdominal wall hematoma, angina bullosa hemorrhagica, disseminated intravascular coagulation, diverticulum intestinal hemorrhagic, eye hematoma, hemorrhage subcutaneous, hemorrhagic stroke, eye hemorrhage, gastrointestinal hemorrhage, gingival bleeding, hematemeses, hepatic hematoma, hepatic hemorrhage, intraabdominal hemorrhage, laryngeal hemorrhage, lower gastrointestinal hemorrhage, melena, menorrhagia, mouth hemorrhage, occult blood positive, esophageal hemorrhage, post procedural hemorrhage, pelvic hematoma, periorbital hematoma, periorbital hemorrhage, pharyngeal hemorrhage, postmenopausal hemorrhage, pulmonary contusion, purpura, retinal hemorrhage, retroperitoneal hematoma, scleral hemorrhage, skin hemorrhage, subarachnoid hemorrhage, subdural hemorrhage, traumatic hemothorax, tumor hemorrhage, upper gastrointestinal hemorrhage, uterine hemorrhage, vessel puncture site hematoma.

^d Hypothyroidism includes hypothyroidism, blood thyroid stimulating hormone increased, thyroxine free increased, blood thyroid stimulating hormone decreased, thyroxine increased, tri-iodothyronine decreased, thyroid function test abnormal, tri-iodothyronine increased, post procedural hypothyroidism, blood thyroid stimulating hormone abnormal, thyroiditis, tri-iodothyronine free decreased.

^e Diarrhea includes diarrhea, anal incontinence, defecation urgency, frequent bowel movements, gastrointestinal hypermotility.

^f Dry mouth includes dry mouth, mucosal dryness.

^g Abdominal pain includes abdominal pain, abdominal pain upper, abdominal pain lower, abdominal discomfort, gastrointestinal pain.

^h Vomiting includes vomiting, retching, regurgitation.

ⁱ Stomatitis includes stomatitis, mouth ulceration, mucosal inflammation, mucosal blistering.

^j Edema includes edema, edema peripheral, face edema, periorbital edema, eye edema, eyelid edema, orbital edema, localized edema, generalized edema, lymphedema, edema genital, scrotal edema, peripheral swelling, scrotal swelling, swelling, swelling face, eye swelling, angioedema, skin edema, testicular swelling, vulvovaginal swelling.

^k Fatigue includes fatigue, asthenia, malaise.

^l Urinary tract infection includes urinary tract infection, cystitis, escherichia urinary tract infection, escherichia pyelonephritis, kidney infection, nitrite urine present, pyelonephritis, urethritis, urinary tract infection bacterial, urogenital infection fungal, urosepsis.

^m Pneumonia includes pneumonia, lung infection, pneumonia aspiration, empyema, lung consolidation, pleural infection, pneumonia bacterial, pneumonia staphylococccal, atypical pneumonia, lung abscess, pneumocystitis jirovecii pneumonia, pneumonia pneumococcal, pneumonia respiratory syncytial viral.

ⁿ Blood creatinine increased includes blood creatinine increased, acute kidney injury, renal failure, renal impairment.

^o ECG QT prolonged includes electrocardiogram QT prolonged, electrocardiogram QT interval abnormal.

^p Headache includes headache, sinus headache, tension headache.

^q Dizziness includes dizziness, vertigo, presyncope, dizziness postural.

- ^r Erectile dysfunction includes erectile dysfunction, organic erectile dysfunction, and psychogenic erectile dysfunction.
- ^s Based on male patients treated with selpercatinib (n=426).
- ^t Cough includes cough, productive cough.
- ^u Dyspnea includes dyspnea, dyspnea exertional, dyspnea at rest.
- ^v Rash includes rash, rash erythematous, rash macular, rash maculopapular, rash morbilliform, rash pruritic, skin exfoliation, dermatitis, urticaria, rash pruritic, exfoliative rash, rash popular, dermatitis allergic, rash follicular, rash generalized, rash pustular, butterfly rash, rash vesicular.
- ^w Hypertension includes hypertension, blood pressure increased.

LIBRETTO-431

The safety of RETEVMO as an initial treatment of patients with unresectable locally advanced or metastatic *RET* fusion-positive NSCLC has been evaluated in LIBRETTO-431. This was a randomized, open-label, multi-center phase 3 study. Patients were randomized 1.6:1 to receive RETEVMO as a single agent administered at 160 mg orally twice daily or a platinum-based therapy plus pemetrexed with or without pembrolizumab. Patients who were stratified with the investigator's intent to be treated without pembrolizumab was restricted to no more than 20%. Among the 158 patients who received RETEVMO, the median duration of exposure was 16.7 months (range: 5 days to 37.9 months). The median age was 61.0 years (range: 31-87 years); 46.2% were male and 59.7% were Asian, 37.0% were White and 1.3% were Black. At study entry, 94.3% of patients had stage IV disease and 5.7% of patients had stage IIIB disease.

Treatment-emergent adverse events reported in $\geq 10\%$ of patients treated with RETEVMO in LIBRETTO-431 are listed in Table 6.

Table 6 TEAEs Occurring in $\geq 10\%$ of Patients Administered with RETEVMO for the Initial Treatment of Metastatic *RET* Fusion-Positive NSCLC (LIBRETTO-431)

System Organ Class Preferred Term ^a	RETEVMO N=158		Chemotherapy with or without pembrolizumab N=98	
	All Grades ^b n (%)	Grade 3 or 4 n (%)	All Grades ^b n (%)	Grade 3 or 4 n (%)
Endocrine disorders				
Hypothyroidism ^c	20 (12.7)	0	16 (16.3)	0
Gastrointestinal disorders				
Diarrhea	69 (43.7)	2 (1.3)	24 (24.5)	2 (2.0)
Dry mouth	61 (38.6)	0	6 (6.1)	0
Abdominal pain ^d	40 (25.3)	1 (0.6)	19 (19.4)	2 (2.0)
Constipation	34 (21.5)	0	39 (39.8)	1 (1.0)
Stomatitis ^e	28 (17.7)	0	16 (16.3)	0
Nausea	20 (12.7)	0	43 (43.9)	1 (1.0)
Vomiting	20 (12.7)	0	23 (23.5)	1 (1.0)
General disorders and administrative site conditions				
Edema ^f	65 (41.1)	4 (2.5)	27 (27.6)	0

System Organ Class Preferred Term ^a	RETEVMO N=158		Chemotherapy with or without pembrolizumab N=98	
	All Grades ^b n (%)	Grade 3 or 4 n (%)	All Grades ^b n (%)	Grade 3 or 4 n (%)
Fatigue ^g	51 (32.3)	5 (3.2)	49 (50.0)	5 (5.1)
Pyrexia	21 (13.3)	1 (0.6)	23 (23.5)	0
Infections and Infestations				
Urinary tract infections ^h	24 (15.2)	1 (0.6)	7 (7.1)	0
Investigations				
ECG QT prolonged	32 (20.3)	14 (8.9)	1 (1.0)	0
Weight increased	23 (14.6)	2 (1.3)	7 (7.1)	0
Gamma-glutamyl transferase increased	20 (12.7)	4 (2.5)	10 (10.2)	0
Metabolism and Nutrition disorders				
Decreased appetite	27 (17.1)	0	33 (33.7)	2 (2.0)
Musculoskeletal and connective tissue disorders				
Arthralgia	17 (10.8)	0	9 (9.2)	0
Nervous system				
Headache	22 (13.9)	0	10 (10.2)	0
Respiratory Thoracic				
Cough ⁱ	20 (12.7)	0	16 (16.3)	1 (1.0)
COVID-19	30 (19.0)	1 (0.6)	18 (18.4)	0
Skin and subcutaneous				
Rash ^j	52 (32.9)	3 (1.9)	29 (29.6)	1 (1.0)
Vascular				
Hypertension	76 (48.1)	32 (20.3)	7 (7.1)	3 (3.1)

^a Reported adverse event terms were coded using MedDRA (version 26.0).

^b The severity of TEAEs was graded based on the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 5.0.

^c Hypothyroidism includes blood thyroid stimulating hormone increased, thyroxine increased, hypothyroidism, thyroid disorder, tri-iodothyronine decreased, thyroxine free increased, blood thyroid stimulating hormone decreased, thyroxine free decreased, tri-iodothyronine abnormal, thyroid function test abnormal

^d Abdominal pain includes abdominal pain, abdominal pain upper, abdominal discomfort, abdominal pain lower, gastrointestinal pain.

^e Stomatitis includes stomatitis, mouth ulceration, mucosal inflammation.

^f Edema includes edema peripheral, face edema, edema, periorbital edema, swelling face, peripheral swelling, penile edema, scrotal edema, eye edema, eyelid edema, localized edema, orbital edema, periorbital swelling, orbital swelling.

- ^g Fatigue includes fatigue, asthenia, malaise.
- ^h Urinary tract infection includes urinary tract infection, cystitis, dysuria, asymptomatic bacteriuria, protein urine present, red blood cells urine positive, urosepsis
- ⁱ Cough includes cough, productive cough.
- ^j Rash includes rash, dermatitis, rash maculopapular, skin exfoliation, dermatitis allergic rash erythematous, rash macular, urticaria rash papular, rash pustular, rash vesicular, urticaria.

LIBRETTO-531

The safety of RETEVMO in the treatment of patients with advanced, kinase inhibitor-naïve, *RET*-mutant MTC has been evaluated in LIBRETTO-531. This was a randomized, open-label, multi-center, phase 3 study. Patients were randomized in a 2:1 ratio to receive RETEVMO as a single agent administered at 160 mg orally twice daily or the physician's choice of cabozantinib or vandetanib. The only one adolescent patient enrolled in the study had a weight-based dosing of RETEVMO (40 mg/m²). Among the 193 patients who received RETEVMO, the median duration of exposure was 14.9 months (range: 0.8 months to 36.5 months). The median age of these patients was 56.0 years (range: 12-79 years); 70.7% were White, 26.2% were Asian and 3.0% were Black. At study entry, 73.1% of patients in the RETEVMO group and 84.7% in the control arm had distant metastases.

TEAEs reported in ≥10% of patients treated with Retevmo in LIBRETTO-531 are listed in table 7.

Table 7 - TEAEs Occurring in ≥10% of Patients Administered with RETEVMO for the Treatment of Advanced or Metastatic, Kinase Inhibitor-Naïve, *RET*-mutant MTC (LIBRETTO-531)

System Organ Class Preferred Term ^a	RETEVMO N=193		Cabozantinib or Vandetanib N=97	
	All Grades ^b n (%)	Grade 3 or 4 n (%)	All Grades ^b n (%)	Grade 3 or 4 n (%)
Endocrine				
Hypothyroidism ^c	22 (11.4)	0	17 (17.5)	0
Gastrointestinal				
Dry mouth	61 (31.6)	1 (0.5)	10 (10.3)	1 (1.0)
Diarrhea	51 (26.4)	6 (3.1)	59 (60.8)	8 (8.2)
Abdominal pain ^d	35 (18.1)	1 (0.5)	20 (20.6)	2 (2.1)
Constipation	31 (16.1)	0 (0.0)	12 (12.4)	0 (0.0)
Stomatitis ^e	27 (14.0)	1 (0.5)	41 (42.3)	13 (13.4)
Nausea	20 (10.4)	2 (1.0)	31 (32.0)	5 (5.2)
General disorders and administrative site conditions				
Edema ^f	63 (32.6)	0	5 (5.2)	0
Fatigue ^g	54 (28.0)	8 (4.1)	46 (47.4)	9 (9.3)
Pyrexia	23 (11.9)	2 (1.0)	2 (2.1)	0
Infections and Infestations				
COVID-19	20 (10.4)	0	17 (17.5)	0

System Organ Class Preferred Term ^a	RETEVMO N=193		Cabozantinib or Vandetanib N=97	
	All Grades ^b n (%)	Grade 3 or 4 n (%)	All Grades ^b n (%)	Grade 3 or 4 n (%)
Investigations				
ECG QT prolonged	26 (13.5)	9 (4.7)	13 (13.4)	2 (2.1)
Weight increased	22 (11.4)	3 (1.6)	2 (2.1)	0
Metabolism and Nutrition				
Decreased appetite	23 (11.9)	1 (0.5)	27 (27.8)	5 (5.2)
Nervous system				
Headache	44 (22.8)	1 (0.5)	20 (20.6)	0
Reproductive system and breast disorders				
Erectile dysfunction ^h	12 (10.4)	0	0	0
Respiratory Thoracic				
Cough ⁱ	20 (10.4)	0	7 (7.2)	0
Skin and subcutaneous				
Rash ^j	36 (18.7)	3 (1.6)	26 (26.8)	4 (4.1)
Vascular				
Hypertension ^k	83 (43.0)	37 (19.2)	40 (41.2)	17 (17.5)

^a Reported adverse event terms were coded using MedDRA (version 26.0).

^b The severity of TEAEs was graded based on the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 5.0.

^c Hypothyroidism includes hypothyroidism, blood thyroid stimulating hormone decreased, blood thyroid stimulating hormone increased, thyroidectomy.

^d Abdominal pain includes abdominal pain, abdominal pain upper, abdominal discomfort, abdominal pain lower, gastrointestinal pain.

^e Stomatitis includes stomatitis, mouth ulceration, mucosal inflammation.

^f Edema includes edema peripheral, face edema, periorbital edema, edema, eyelid edema, localized edema, face swelling, swelling of the eyelid, periorbital swelling, peripheral swelling, swelling, eye swelling, generalized edema.

^g Fatigue includes fatigue, asthenia, malaise.

^h Gender specific event for males – denominator adjusted: erectile dysfunction.

ⁱ Cough includes cough, productive cough.

^j Rash includes rash, rash maculo-papular, dermatitis, rash pustular, skin exfoliation, dermatitis allergic, rash erythematous, rash papular, rash pruritic, skin reaction, urticaria.

^k Hypertension includes hypertension, blood pressure increased.

Erectile dysfunction has been observed more commonly in male patients with *RET*-mutant medullary thyroid cancer (25.9%) treated with selpercatinib compared to male patients with *RET* fusion-positive NSCLC or advanced thyroid cancer (6.5% and 12.5% respectively) in LIBRETTO-001.

8.3 Less Common Clinical Trial Adverse Reactions

Additional less common treatment-emergent adverse events (all grades) occurring at an overall incidence <10% and ≥1% of patients treated with RETEVMO in any of the above studies included:

Blood and lymphatic system disorders: eosinophilia, leukocytosis, leukopenia, lymphadenopathy, lymphopenia, polycythemia.

Cardiac disorders: angina pectoris, atrial fibrillation, bradycardia, cardiac failure, myocardial infarction, palpitations, pericardial effusion, sinus bradycardia, sinus tachycardia, supraventricular extrasystoles, tachycardia.

Ear and labyrinth disorders: ear pain, hypoacusis, tinnitus,

Endocrine disorders: adrenal insufficiency, hyperthyroidism.

Eye disorders: blepharitis, cataract, dry eye, glaucoma, keratitis, lacrimation increased, ocular hyperemia, vision blurred, visual acuity reduced, visual impairment, vitreous floaters.

Gastrointestinal disorders: aphthous ulcer, chronic gastritis, colitis, dental carries, diverticulum, dyspepsia, dysphagia, enteritis, enterocolitis, eructation, esophagitis, feces hard, flatulence, gastritis, gastritis erosive, gastrointestinal wall thickening, glossodynia, hematochezia, hemorrhoids, ileus, inguinal hernia, large intestine polyp, odynophagia, oral dysaesthesia, oral pain, toothache, umbilical hernia.

General disorders and administration site conditions: chest discomfort, chest pain, chills, gait disturbance, influenza-like illness, non-cardiac chest pain, pain, generalized physical health deterioration, temperature intolerance, thirst, xerosis.

Hepatobiliary disorders: cholecystitis, cholelithiasis, hepatic cyst, hepatic cytolysis, hepatic function abnormal, hepatic steatosis, hepatic stenosis, immune-mediated hepatic disorder.

Immune system disorders: contrast media allergy, seasonal allergy.

Infections and infestations: bacterial disease carrier, bronchitis, cellulitis, conjunctivitis, dengue fever, diverticulitis, ear infection, eye infection, folliculitis, gastroenteritis, gastroenteritis viral, gastrointestinal infection, herpes zoster, influenza, laryngitis, lower respiratory tract infection, nasopharyngitis, oral candidiasis, oral herpes, otitis media, paronychia, pharyngitis, respiratory tract infection, rhinitis, sepsis, sinusitis, skin candida, skin infection, tooth abscess, tooth infection, vaginal infection, vulvovaginal candidiasis, vulvovaginal mycotic infection.

Investigations: amylase increased, blood bicarbonate decreased, blood creatine phosphokinase increased, blood lactate dehydrogenase increased, blood phosphorus increased, blood urea increased, blood uric acid increased, colonoscopy, coronavirus test positive, eosinophil count increased, gamma-glutamyltransferase increased, hematocrit increased, hepatic enzyme increased, lipase increased, liver function test increased, sars-cov-2 test positive, transaminases increased, urobilinogen urine increased.

Metabolism and nutrition disorders: dehydration, dyslipidemia, gout, hypercholesterolemia, hyperglycemia, hyperkalemia, hyperlipidemia, hypermagnesemia, hypertriglyceridemia, hyperuricemia, hypochloremia, hypoglycemia, hypophosphatemia, hypoproteinemia, iron deficiency, vitamin b12 deficiency, vitamin d deficiency

Musculoskeletal and connective tissue disorders: arthritis, back pain, bone pain, flank pain, groin pain, intervertebral disc protrusion, joint swelling, muscle spasms, muscular weakness, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal stiffness, neck pain,

osteoarthritis, pain in jaw, plantar fasciitis, slipped capital femoral epiphysis/slipped upper femoral epiphysis (pediatric and adolescent patients), spinal osteoarthritis.

Neoplasms benign, malignant and unspecified: basal cell carcinoma, cancer pain, prostate cancer, skin papilloma, squamous cell carcinoma of skin, tumor pain, uterine leiomyoma.

Nervous system disorders: amnesia, anosmia, aphasia, ataxia, balance disorder, cerebrovascular accident, cognitive disorder, disturbance in attention, dysarthria, dysgeusia, hypoesthesia, memory impairment, migraine, neuralgia, neuropathy peripheral, paresthesia, peripheral motor neuropathy, peripheral sensory neuropathy, sciatica, seizure, somnolence, syncope, taste disorder, transient ischemic attack, tremor.

Psychiatric disorders: agitation, anxiety, confusional state, delirium, depression, libido decreased, loss of libido.

Renal and urinary disorders: micturition urgency, nephrolithiasis, pollakiuria, proteinuria, renal cyst, urinary hesitation, urinary incontinence, urinary retention, urinary tract pain.

Reproductive system and breast disorders: adenomyosis, amenorrhea, benign prostatic hyperplasia, gynaecomastia, menstruation delayed, menstruation irregular, ovarian cyst, pelvic fluid collection, pelvic pain, polycystic ovaries, prostatitis, testicular pain, uterine prolapse, vaginal prolapse.

Respiratory, thoracic and mediastinal disorders: aphonia, chylous ascites, chylothorax, dry throat, hypoxia, interstitial lung disease, interstitial lung disease/pneumonitis, lower respiratory tract congestion, nasal congestion, nasal dryness, oropharyngeal pain, pleuritic pain, pneumonitis, pneumothorax, pulmonary embolism, respiratory failure, rhinitis allergic, rhinorrhea, sinus congestion, upper-airway cough syndrome, wheezing.

Skin and subcutaneous tissue disorders: acne, actinic keratosis, decubitus ulcer, dermatitis acneiform, dermatitis contact, ecchymosis, eczema, erythema, hyperhidrosis, hyperkeratosis, ingrowing nail, nail disorder, nail dystrophy, night sweats, onychoclasia, pain of skin, palmar-plantar erythrodysesthesia syndrome, photosensitivity reaction, pruritis, rosacea, scar pain, skin discoloration, skin exfoliation, skin hyperpigmentation, skin lesion, skin mass, skin ulcer, xeroderma.

Surgical and medical procedures: colporrhaphy, hysterectomy, transurethral prostatectomy.

Vascular disorders: embolism, flushing, hot flush, hypotension, lymphedema, orthostatic hypotension, peripheral coldness, Raynaud's phenomenon.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

Clinical Trial Findings

The following tables (8, 9, and 10) provide treatment-emergent shifts from baseline in laboratory abnormalities occurring in patients treated with RETEVMO in the LIBRETTO-001, LIBRETTO-431, and LIBRETTO-531 studies.

LIBRETTO-001

Table 8 - Laboratory Abnormalities Worsening from Baseline in $\geq 15\%$ of Patients with Metastatic *RET*-Altered Solid Tumors Treated with RETEVMO in LIBRETTO-001

Laboratory Abnormality ^b	RETEVMO ^a	
	All Grades n (%)	Grade 3 or 4 n (%)
Chemistry		
Increased AST	511 (61)	87 (10)
Decreased calcium	507 (61)	62 (7)
Decreased albumin	497 (60)	29 (3)
Increased ALT	473 (57)	102 (12)
Increased glucose	461 (55)	31 (4)
Increased creatinine	425 (51)	30 (4)
Decreased sodium	395 (47)	107 (13)
Increased alkaline phosphatase	355 (43)	36 (4)
Increased potassium	322 (39)	27 (3)
Decreased glucose	318 (38)	11 (1)
Increased total cholesterol	303 (37)	14 (2)
Decreased magnesium	300 (36)	5 (1)
Increased bilirubin	257 (31)	24 (3)
Decreased phosphate	194 (23)	37 (4)
Decreased potassium	181 (22)	21 (3)
Hematology		
Decreased lymphocytes	444 (55)	174 (22)
Decreased white blood cells	423 (51)	24 (3)
Decreased platelets	336 (40)	32 (4)
Decreased hemoglobin	282 (34)	33 (4)
Decreased neutrophil count	215 (26)	29 (4)

^a Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 806 to 834 patients.

^b The severity of TEAEs was graded based on the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 4.03, except for increased creatinine, which was based on v5.0.

LIBRETTO-431

Table 9 - Laboratory Abnormalities Worsening from Baseline in $\geq 15\%$ of Patients Administered with RETEVMO for the Initial Treatment of Metastatic *RET* Fusion-Positive NSCLC (LIBRETTO-431)

Laboratory Abnormality	RETEVMO ^a		Chemotherapy with or without pembrolizumab ^b	
	All Grades ^c n (%)	Grade 3 or 4 n (%)	All Grades ^c n (%)	Grade 3 or 4 n (%)
Chemistry				
Increased ALT	127 (80.9)	33 (21.0)	61 (62.9)	4 (4.1)
Increased AST	120 (76.9)	15 (9.6)	45 (46.4)	0
Decreased calcium	82 (52.6)	3 (1.9)	23 (23.7)	1 (1.0)
Increased total bilirubin	81 (51.6)	2 (1.3)	9 (9.4)	0
Increased alkaline phosphatase	55 (35.0)	2 (1.3)	21 (21.7)	0
Decreased sodium	48 (30.8)	5 (3.2)	40 (41.2)	2 (2.1)
Increased magnesium	42 (26.9)	3 (1.9)	15 (15.5)	0
Increased potassium	40 (25.8)	4 (2.6)	15 (15.5)	1 (1.0)
Decreased albumin	39 (24.8)	0	5 (5.2)	0
Increased blood creatinine	36 (22.9)	0	20 (20.6)	0
Increased sodium	34 (21.8)	0	13 (13.4)	0
Increased calcium	28 (18.0)	0	25 (25.8)	0
Decreased potassium	27 (17.4)	2 (1.3)	15 (15.5)	1 (1.0)
Decreased magnesium	25 (16.0)	1 (0.6)	8 (8.3)	0
Hematology				
Decreased white blood cell count	87 (56.5)	2 (1.3)	60 (61.9)	9 (9.3)
Decreased lymphocyte count	82 (53.3)	13 (8.4)	62 (63.9)	15 (15.5)
Decreased neutrophil count	82 (53.3)	3 (2.0)	56 (57.7)	11 (11.3)
Decreased platelets	81 (52.6)	5 (3.3)	38 (39.2)	5 (5.2)
Decreased hemoglobin	33 (21.4)	0	88 (90.7)	5 (5.2)
Increased hemoglobin	31 (20.1)	0	1 (1.0)	0

^a Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 154 to 157 patients.

^b Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 96 to 97 patients.

^c The severity of TEAEs was graded based on the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 5.0

LIBRETTO-531

Table 10 - Laboratory Abnormalities Worsening from Baseline in $\geq 15\%$ of Patients Administered with RETEVMO for the Treatment of Advanced or Metastatic, Kinase Inhibitor-Naïve, *Ret*-mutant MTC (LIBRETTO-531)

Laboratory Abnormality	RETEVMO ^a		Cabozantinib or Vandetanib ^b	
	All Grades ^c n (%)	Grade 3 or 4 n (%)	All Grades ^c n (%)	Grade 3 or 4 n (%)
Chemistry				
Decreased calcium	103 (55.1)	10 (5.4)	57 (62.0)	10 (10.9)
Increased ALT	97 (53.0)	30 (16.4)	66 (71.7)	6 (6.5)
Increased AST	87 (46.5)	10 (5.4)	64 (68.1)	3 (3.2)
Increased alkaline phosphatase	68 (36.8)	11 (6.0)	26 (28.0)	5 (5.4)
Increased blood bilirubin	60 (31.9)	2 (1.1)	28 (29.8)	3 (3.2)
Increased creatinine	50 (26.9)	11 (5.9)	15 (16.3)	7 (7.6)
Increased potassium	38 (20.5)	3 (1.6)	10 (10.9)	0
Decreased sodium	37 (19.9)	6 (3.2)	15 (16.3)	0
Increased calcium	31 (16.6)	5 (2.7)	8 (8.7)	2 (2.2)
Hematology				
Decreased lymphocytes	78 (41.1)	35 (18.4)	34 (36.2)	12 (12.8)
Decreased white blood cells	75 (39.3)	4 (2.1)	36 (38.3)	5 (5.3)
Decreased neutrophil count	63 (33.0)	27 (14.1)	39 (41.5)	18 (19.2)
Increased hemoglobin	55 (28.8)	17 (8.9)	39 (41.5)	8 (8.5)
Decreased platelets	53 (28.0)	2 (1.1)	32 (34.0)	1 (1.1)

^a Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 183 to 191 patients.

^b Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 91 to 94 patients.

^c The severity of TEAEs was graded based on the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v 5.0

Electrocardiograms: QTc interval prolongation was reported in patients receiving RETEVMO in clinical trials. In the LIBRETTO-001 trial, the mean change from baseline QTcF averaged 18-22 ms at 2 h post-dosing from day 8 of treatment onward in patients initiated at the 160 mg twice daily dose of RETEVMO. Treatment-emergent QTcF values >480 ms and >500 ms were reported in 20.1% and 8.1% of patients, respectively. In LIBRETTO-431 and LIBRETTO-531 trials, QTc Interval >500 ms were reported in 5.1% and 3.7%, respectively. QTcF increases in all trials from baseline >60 ms were reported in 16.7% to 21.6% of patients (see [7 Warnings and Precautions](#) and [10.2 Pharmacodynamics](#)).

Treatment with selpercatinib 160 mg BID was also associated with decreases from baseline in heart rate that averaged about -5 bpm to -9 bpm and increases from baseline in the PR interval that averaged about 5 ms to 9 ms from day 8 onward at 2 h post-dosing.

8.5 Post-Market Adverse Reactions

The following adverse reaction has been identified during post-approval use of RETEVMO. Because such reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Skin and subcutaneous tissue disorders: Stevens-Johnson Syndrome

9 Drug Interactions

9.2 Drug Interactions Overview

Selpercatinib is a substrate of CYP3A4 and it is predominantly metabolized by CYP3A4.

Coadministration of RETEVMO with a moderate or strong CYP3A4 inhibitor may increase selpercatinib plasma concentrations, which may increase the risk of adverse reactions related to RETEVMO, including QTc interval prolongation.

Coadministration of RETEVMO with a moderate or strong CYP3A4 inducer may decrease selpercatinib plasma concentrations.

Coadministration of RETEVMO with CYP3A4-sensitive substrates may increase plasma concentrations of the CYP3A4 substrates. Coadministration of RETEVMO with sensitive CYP2C8 substrates may increase plasma concentrations of the CYP2C8 substrates.

Selpercatinib inhibits the renal transporter multidrug and toxin extrusion protein 1 (MATE1). In vivo interactions of selpercatinib with clinically relevant substrates of MATE1, such as creatinine, may occur. RETEVMO may increase serum creatinine due to inhibition of the renal tubular secretion transporter MATE1, without affecting glomerular function.

Selpercatinib is a substrate and inhibitor of P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).

Concomitant use of RETEVMO with either BCRP or P-gp substrates increases their plasma concentrations, which may increase the risk of adverse reactions related to these substrates.

Concomitant use of RETEVMO with acid-reducing agents may decrease selpercatinib plasma concentrations, which may reduce RETEVMO anti-tumor activity.

9.4 Drug-Drug Interactions

The effects of other drugs on RETEVMO are listed in Table 11. The effects of RETEVMO on other drugs are listed in Table 12. The drugs listed in these tables are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction. This list is not exhaustive.

Table 11 - Effects of Other Drugs on RETEVMO

Common Name	Source of Evidence	Effect	Clinical Comment
Drugs that may increase selpercatinib plasma concentrations			
Strong CYP3A4 inhibitors, including but not limited to itraconazole, clarithromycin, voriconazole, ketoconazole, ritonavir, telithromycin, posaconazole	CT, T	Coadministration of multiple doses of itraconazole (200 mg QD) with a single dose of selpercatinib 160 mg increased the selpercatinib AUC _{0-INF} by 133% and C _{max} by 30%.	Concomitant use of RETEVMO with a strong CYP3A4 inhibitor may increase the risk of adverse reactions associated with RETEVMO, including QTc interval prolongation. Avoid coadministration of RETEVMO with strong CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the current RETEVMO dose (see 4 Dosage and Administration) and monitor the QTc interval more frequently with ECGs.
Moderate CYP3A4 inhibitors, including but not limited to diltiazem, fluconazole, verapamil, ciprofloxacin	T	Coadministration of multiple doses of diltiazem (60 mg TID), fluconazole (200 mg QD), or verapamil (80 mg TID) with multiple doses of selpercatinib (160 mg BID) is predicted by modelling to increase the selpercatinib AUC by 60-99% and C _{max} by 46-76%.	Concomitant use of RETEVMO with a moderate CYP3A inhibitor may increase the risk of adverse reactions associated with RETEVMO, including QTc interval prolongation. Avoid coadministration of RETEVMO with moderate CYP3A4 inhibitors. If coadministration cannot be avoided, reduce the current RETEVMO dose (see 4 Dosage and Administration) and monitor the QTc interval more frequently with ECGs.

Common Name	Source of Evidence	Effect	Clinical Comment
Drugs that may decrease selpercatinib plasma concentrations			
Strong CYP3A4 inducers, including but not limited to rifampin, phenytoin, phenobarbital, carbamazepine, dexamethasone, rifabutin	CT, T	Coadministration of multiple doses of rifampin 600 mg QD with a single dose of selpercatinib 160 mg decreased the selpercatinib AUC _{0-INF} by 87% and C _{max} by 70%.	Concomitant use of RETEVMO with a strong CYP3A inducer may reduce RETEVMO anti-tumor activity. Avoid coadministration of RETEVMO with strong CYP3A4 inducers.
Moderate CYP3A4 inducers, including but not limited to bosentan, efavirenz	T	Coadministration of multiple doses of bosentan (62.5 mg BID or 125 mg BID) or efavirenz (600 mg QD) with multiple doses of selpercatinib (160 mg BID) is predicted by modelling to decrease the selpercatinib AUC by 40-70%, and C _{max} by 34-57%.	Concomitant use of RETEVMO with a moderate CYP3A inducer may reduce RETEVMO anti-tumor activity. Avoid coadministration of RETEVMO with moderate CYP3A4 inducers.
Weak CYP3A4 inducers, including but not limited to modenafile	T	Coadministration of multiple doses of modenafile (200 mg QD) with multiple doses of selpercatinib (160 mg BID) is predicted to decrease the selpercatinib AUC by 33%, and C _{max} by 26%.	The combination is not predicted to have any clinical effects.

Common Name	Source of Evidence	Effect	Clinical Comment
Proton pump inhibitors (PPIs, including but not limited to omeprazole)	CT	<p>Coadministration with multiple daily doses of omeprazole (40 mg QD) with a single dose of selpercatinib (160 mg) decreased selpercatinib AUC_{0-12h} by 69% and C_{max} by 88% when RETEVMO was administered fasting.</p> <p>Coadministration with multiple daily doses of omeprazole (40 mg QD) with a single dose of selpercatinib (160 mg) after low-fat or high-fat meal did not significantly change the selpercatinib AUC_{0-12h} while the C_{max} decreased by 22% to 49%.</p>	<p>Avoid concomitant administration of a proton pump inhibitor with RETEVMO.</p> <p>If concomitant use cannot be avoided, patients should be advised to take RETEVMO with food when coadministered with a proton pump inhibitor.</p>

Common Name	Source of Evidence	Effect	Clinical Comment
Histamine-2 (H2) receptor antagonists (including but not limited to ranitidine)	CT, T	<p>Selpercatinib has pH-dependent solubility, with decreased solubility at higher pH. H2 receptor antagonists may interfere with selpercatinib bioavailability.</p> <p>No clinically significant differences in selpercatinib pharmacokinetics were observed when coadministered with multiple daily doses of ranitidine (150 mg BID) given 10 hours prior to and 2 hours after the RETEVMO dose (160 mg BID, administered fasting). Selpercatinib AUC_{0-INF} decreased by 7% and C_{max} by 18% on co-administration.</p>	<p>Avoid concomitant administration of a H2 receptor antagonist.</p> <p>If concomitant use cannot be avoided, patients should be advised to take RETEVMO 2 hours before or 10 hours after administration of an H2 receptor antagonist.</p>
Locally acting antacids (including but not limited to calcium carbonate)	T	<p>Selpercatinib has pH-dependent solubility, with decreased solubility at higher pH. Locally acting antacids may interfere with selpercatinib bioavailability.</p>	<p>Avoid concomitant administration of a locally acting antacid</p> <p>If concomitant use cannot be avoided, patients should be advised to take RETEVMO 2 hours before or 2 hours after administration of a locally acting antacid.</p>

Legend: CT=Clinical Trial; T=Theoretical.

Table 12 - Effects of RETEVMO on Other Drugs

Common Name	Source of Evidence	Effect	Clinical Comment
Effect of selpercatinib on sensitive CYP2C8 substrates			
Sensitive CYP2C8 substrates, including but not limited to repaglinide, enzalutamide, paclitaxel, sorafenib, rosiglitazone, pioglitazone, montelukast, selexipag, buprenorphine	CT, T	Coadministration of multiple doses of RETEVMO (160 mg BID) with single dose of repaglinide (0.5 mg QD) increased the repaglinide AUC _{0-INF} by 188% and C _{max} by 91%.	Avoid coadministration of RETEVMO with sensitive CYP2C8 substrates. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling.
Effect of selpercatinib on sensitive CYP3A4 substrates			
Sensitive CYP3A4 substrates, including but not limited to midazolam, alfentanil, avanafil, buspirone, darifenacin, darunavir, everolimus, lomitapide, ibrutinib, lovastatin, naloxegol, simvastatin, tipranavir, triazolam, vardenafil	CT, T	Coadministration of multiple doses of RETEVMO (160 mg BID) with midazolam (2 mg QD) increased the midazolam AUC _{0-INF} by 54% and C _{max} by 39%.	Avoid coadministration of RETEVMO with sensitive CYP3A4 substrates. If coadministration cannot be avoided, modify the substrate dosage as recommended in its product labeling.
Effect of selpercatinib on transporters			
MATE1 substrates, including but not limited to creatinine	T	Selpercatinib inhibits the renal transporter multidrug and toxin extrusion protein 1 (MATE1).	Selpercatinib may increase serum creatinine by decreasing renal tubular secretion of creatinine via inhibition of MATE1. Consider alternative markers of renal function if persistent elevations in serum creatinine are observed, such as cystatin C, BUN, or calculated GFR. No clinically significant differences in glucose levels were observed when metformin (MATE1 substrate) was coadministered with selpercatinib.

Legend: CT=Clinical Trial; T=Theoretical.

P-glycoprotein (P-gp) Inhibitors: Coadministration of single dose of RETEVMO (160 mg QD) with single dose of rifampin (P-gp inhibitor, 600 mg QD) increased the selpercatinib AUC_{0-12h} by 6% and C_{max} by 19% and is not clinically significant.

P-gp Substrates: Coadministration of RETEVMO with dabigatran (P-gp substrate) increased the dabigatran AUC_{0-12h} by 38% and C_{max} by 43%.

Avoid coadministration of RETEVMO with P-gp substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for P-gp substrates provided in their approved product labeling.

BCRP Substrates: Coadministration of RETEVMO with rosuvastatin (BCRP substrate) increased the rosuvastatin AUC_{0-12h} by 80% and C_{max} by 71%. Use caution when co-administering rosuvastatin with RETEVMO.

Avoid coadministration of RETEVMO with BCRP substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration of RETEVMO with a BCRP substrate is necessary, follow recommendations for BCRP substrates provided in their approved product labeling.

In vitro drug interactions: In vitro, selpercatinib does not inhibit or induce CYP1A2, CYP2B6, CYP2C9, CYP2C19, or CYP2D6 at clinically relevant concentrations. Selpercatinib is not a substrate for transporters OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or MATE2-K.

Other QTc Interval-Prolonging Drugs

The concomitant administration of RETEVMO with other drugs known to prolong the QTc interval or induce torsade de pointes should be avoided. Current information sources should be consulted for lists of drugs that prolong the QTc interval.

When it is not feasible to avoid concomitant use of drugs known to prolong the QTc interval, obtain ECGs and serum electrolytes measurements prior to and after initiation of any drug known to prolong the QTc interval. Perform more frequent ECG monitoring as clinically indicated during treatment.

Drugs that Affect Electrolytes

Use of RETEVMO with drugs that can decrease electrolyte levels should be avoided to the extent possible as this may increase the risk of QTc interval prolongation. Such drugs include, but are not limited to, the following: loop diuretics, thiazide and related diuretics, laxatives, enemas, amphotericin B, high-dose corticosteroids, and proton pump inhibitors.

Drugs that Reduce Heart Rate

Avoid using RETEVMO concomitantly with drugs that reduce heart rate, including, but not limited to, beta-blockers, digitalis glycosides, non-dihydropyridine calcium channel blockers, cholinesterase inhibitors, alpha2-adrenoceptor agonists, I_f inhibitors, and sphingosine-1 phosphate receptor modulators.

9.5 Drug-Food Interactions

RETEVMO may be administered with or without food unless coadministered with a proton pump inhibitor (see [4.2 Recommended Dose and Dosage Adjustment](#) and [10.3 Pharmacokinetics](#)). Grapefruit can inhibit cytochrome P450 CYP3A enzymes and potential drug interactions of grapefruit and grapefruit containing products with RETEVMO cannot be ruled out.

9.6 Drug-Herb Interactions

St. John's Wort (*hypericum perforatum*) is a strong CYP3A inducer. Co-administration of St. John's Wort with RETEVMO should be avoided.

9.7 Drug-Laboratory Test Interactions

RETEVMO may increase serum creatinine by decreasing renal tubular secretion of creatinine via inhibition of MATE1, without affecting glomerular function. In healthy subjects administered RETEVMO 160 mg orally twice daily, serum creatinine increased 18% after 10 days. If persistent elevations in serum creatinine are observed, alternative markers of renal function should be considered, such as cystatin C, blood urea nitrogen (BUN), or calculated glomerular filtration rate (GFR).

10 Clinical Pharmacology

10.1 Mechanism of Action

Selpercatinib is an orally available, small molecule kinase inhibitor. In enzyme assays, selpercatinib inhibited the "rearranged during transfection" (RET) receptor tyrosine kinase, VEGFR3 (FLT4) and VEGFR1 (FLT1) kinases with IC₅₀ values ranging from 0.92 nM to 67.6 nM. Selpercatinib also inhibited FGFR1, 2 and 3 at higher concentrations. In cellular assays, selpercatinib inhibited RET at an IC₅₀ approximately 60-fold lower than the IC₅₀ for FGFR1 and 2 and approximately 8-fold lower than the IC₅₀ for VEGFR3. In radioligand binding assays at a concentration of 1 μM, selpercatinib inhibited the 5-HT transporter (70.2%) and the α2C receptor (51.7%).

Chromosomal rearrangements involving in-frame fusions of *RET* with various partners can result in constitutively activated chimeric RET fusion proteins that can act as oncogenic drivers, promoting cell proliferation and survival in tumor cell lines. Point mutations in *RET* can also result in constitutively activated RET proteins that can promote cell growth and survival in tumor cell lines.

In RET enzyme assays, selpercatinib inhibits the kinase activity of wild type RET and multiple mutated forms of RET (RET-V804L, RET-V804M, RET-A883F, RET-S904F, and RET-M918T) with IC₅₀ values of 0.20 nM to 2.21 nM.

Selpercatinib demonstrated in vitro inhibition of human cancer cell lines derived from multiple tumor types harboring *RET* fusion genes and *RET* mutations with EC₅₀ values equal to 10 nM or less. In in vivo mouse studies, selpercatinib demonstrated inhibition of tumor growth in *RET* fusion and *RET* mutant cancer cell lines, patient-derived *RET* fusion xenograft models, and a patient-derived *RET* fusion xenograft model harboring a *RET* V804M mutation. Selpercatinib also exhibited intracranial anti-tumor activity of patient-derived *RET* fusion xenograft tumors implanted directly into the brain of mice.

10.2 Pharmacodynamics

Cardiac Electrophysiology

In a randomised, double-blind, placebo- and positive controlled, 4-way crossover ECG assessment study in 32 healthy subjects, selpercatinib at single suprathreshold doses of 320 mg and 640 mg was associated with a concentration-dependent prolongation of the QTcF interval (QTcF=QT/RR^{0.33}). The maximum difference from placebo in mean change from baseline QTcF was 8.1 ms (90% CI 4.3, 11.9) at 12 h post-dosing in the 320 mg arm and 9.7 ms (90% CI 7.0, 12.5) at 2.5 h post-dosing in the 640 mg treatment arm. The mean C_{max}

values were 2024 ng/mL and 2356 ng/mL after the single 320 mg and 640 mg doses, respectively.

According to a pharmacokinetic-pharmacodynamic model, the predicted magnitude of QTcF prolongation is 10.7 ms (90% CI 9.3, 12.2) at the mean steady-state C_{max} value of 2980 ng/mL reported for the 160 mg twice-daily therapeutic dose administered for 8 days to cancer patients and 16.8 ms (90% CI 14.4, 19.2) at the mean steady-state C_{max} value of 4574 ng/mL reported for the 160 mg twice-daily dose administered for 9 days to healthy subjects.

On day 8 of treatment in cancer patients (N=564) initiated at the 160 mg twice-daily dose of RETEVMO in the uncontrolled LIBRETTO-001 trial, the mean change from baseline QTcF was 22.4 ms (95% CI 20.6, 24.2) at 2 h post-dosing.

10.3 Pharmacokinetics

The capsule and tablet dosage forms of selpercatinib are bioequivalent.

The pharmacokinetics of selpercatinib were evaluated in patients with locally advanced or metastatic solid tumors administered 160 mg capsules twice daily unless otherwise specified. Steady-state selpercatinib AUC and C_{max} increased in a slightly greater than dose proportional manner over the dose range of 20 mg once daily to 240 mg twice daily (0.06 to 1.5 times the maximum recommended total daily dosage).

Steady-state was reached by approximately 7 days and the median accumulation ratio after administration of 160 mg twice daily was 3.4-fold for AUC and 2.66 for C_{max}. Mean steady-state selpercatinib C_{max} was 2,980 ng/mL, AUC_{0-24h} was 51,600 ng*h/mL, t_{1/2} was 24.5 hours and CL_{ss}/F was 6 L/hr after administration of selpercatinib 160 mg BID in cancer patients (Table 13). The pharmacokinetics of selpercatinib were comparable between cancer patients and healthy volunteers.

Table 13 - Summary of Selpercatinib Pharmacokinetic Parameters in Cancer Patients Administered 160 mg BID at Steady State

	C _{max} (CV%)	t _{max} (CV%)	AUC _{0-24h} (CV%)	t _{1/2} (CV%)	CL _{ss} /F (CV%)	V _{ss} /F (CV%)
Steady state mean	2980 ng/mL (53.1%)	2 h (8.1%)	51600 ng*h/mL (57.9%)	24.5 h (68.3%)	6.0 L/h (57.9%)	191 L (69%)

CV% = coefficient of variation.

Absorption

After an oral dose of 160 mg in adult patients and in healthy subjects, selpercatinib was rapidly absorbed, with t_{max} of approximately 2 hours. The geometric mean of absolute oral bioavailability of selpercatinib in healthy subjects was 73.2%.

Effect of food:

Capsule: Compared to selpercatinib AUC_T, C_{max} and T_{max} in the fasted state, selpercatinib AUC_T was increased by 9% and C_{max} was reduced by 14% and T_{max} was delayed from 1.5 hours to 4.0 hours after oral administration of a single 160 mg dose (2 x 80 mg capsules) to healthy subjects taken with a high-fat, high calorie meal.

Tablet: Compared to selpercatinib AUC_T , C_{max} and T_{max} in the fasted state, selpercatinib AUC_T was similar, C_{max} was reduced by 17%, and T_{max} was delayed from 1.5 hours to 2.75 hours after oral administration of a single 160 mg dose (1 x 160 mg tablet) to healthy subjects taken with a high-fat, high calorie meal.

Distribution

The apparent volume of distribution (V_{ss}/F) of selpercatinib is 191 L. Protein binding of selpercatinib is 97% in vitro and is independent of concentration. The blood- to-plasma concentration ratio is 0.7.

Metabolism

Selpercatinib is metabolized predominantly by CYP3A4. Following oral administration of a single [^{14}C] radiolabeled 160 mg dose of selpercatinib to healthy subjects, unchanged selpercatinib constituted 86% of the radioactive drug components in plasma.

Excretion

Following oral administration of a single [^{14}C] radiolabeled 160 mg dose of selpercatinib to healthy subjects, 69% of the administered radioactivity was recovered in feces and 24% was recovered in urine.

Special Populations and Conditions

- **Pediatrics** Very limited pharmacokinetics data are available for patients 15 to 17 years of age. There are no data on the pharmacokinetics of selpercatinib in pediatric patients younger than 15 years of age.
- **Geriatrics** Based on a population pharmacokinetic analysis of the LIBRETTO-001 study, the pharmacokinetics of selpercatinib in patients ≥ 65 years of age were comparable to patients between 18 years to 65 years.
- **Patients with body weight <50 kg** The apparent volume of distribution and clearance of selpercatinib increase with increasing body weight (27 kg to 177 kg). In subjects <50 kg, the AUC_{0-12} and the C_{max} of selpercatinib were respectively approximately 50% and 70% higher than in subjects with bodyweights 70-80 kg. Dosing adjustment is required in subjects < 50 kg (see [4 Dosage and Administration](#)).
- **Hepatic insufficiency** In subjects with mild or severe hepatic impairment according to the Child-Pugh classification, unbound AUC_{inf} of selpercatinib increased approximately by 33%, and 228.4% respectively and unbound C_{max} increased by approximately 78.2%, and 131.6% respectively, compared to subjects with normal hepatic function. No changes in unbound AUC_{inf} and unbound C_{max} were observed in subjects with moderate hepatic impairment. No dose adjustment is recommended for patients with mild or moderate hepatic impairment. Reduce the dose of RETEVMO in patients with severe hepatic impairment to 80 mg twice daily (see [4 Dosage and Administration](#) and [7.1 Special Populations](#)).
- **Renal insufficiency** In subjects with mild (eGFR: 60 – <90 ml/min/1.73m²), moderate (eGFR: 30 – 59 ml/min/1.73m²), or severe (eGFR: <30 ml/min/1.73m²) renal impairment administered selpercatinib 160 mg QD, AUC_{inf} of selpercatinib increased by approximately 21.7%, 50.1%, and 12.5% respectively in subjects with mild, moderate or severe renal impairment compared to subjects with normal renal function. C_{max} of selpercatinib increased by 69%, 29.5% and decreased by 14.7% in subjects with mild, moderate or severe renal impairment compared to subjects with normal renal function. No dosage adjustment is necessary in patients with mild, moderate or severe renal impairment.

The effect of end-stage renal disease on the pharmacokinetics and safety of selpercatinib have not been evaluated. The use of selpercatinib in patients with end-stage renal disease is not recommended.

- **Ethnic Origin, sex** Based on a population pharmacokinetic analysis, ethnic origin and sex had no clinically meaningful effect on the pharmacokinetics of selpercatinib.

11 Storage, Stability and Disposal

Store at room temperature (15° to 30°C).

12 Special Handling Instructions

This information is not available for this drug product.

Part 2: Scientific Information

13 Pharmaceutical Information


Drug Substance

Non-proprietary name of the drug substance: selpercatinib

Chemical name: IUPAC: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile]

Molecular formula and molecular mass: $C_{29}H_{31}N_7O_3$; formula weight of 525.6 g/mol

Structural formula:



Capsule Physicochemical properties: Selpercatinib is an anhydrous, crystalline (Form A), white to practically white to light yellow powder. The aqueous solubility of selpercatinib is pH dependent, from sparingly soluble at low pH (≥ 10 mg/mL at pH 1.3) to practically insoluble at neutral pH (0.002 mg/mL at pH 7.5).

Tablet Physicochemical properties: Selpercatinib is an anhydrous, crystalline (Form B), white to practically white to light yellow powder. The aqueous solubility of selpercatinib is pH dependent, from sparingly soluble at low pH (≥ 10 mg/mL at pH 1.3) to practically insoluble at neutral pH (0.004 mg/mL at pH 7.1).

14. Clinical Trials

14.1 Clinical Trials by Indication

Metastatic *RET* Fusion-Positive Non-Small Cell Lung Cancer

LIBRETTO-001

Table 14 - Summary of Patient Demographics for Clinical Trials in Metastatic *RET* Fusion-Positive NSCLC - LIBRETTO-001

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex, n (%)
LIBRETTO-001	Open label, multicenter, multi-cohort, Phase 1/2 study	Patients received RETEVMO 160 mg orally twice daily until unacceptable	Patients previously treated with platinum-based chemotherapy (247)	61 (23-81) years	Male: 107 (43) Female: 140 (57)

		toxicity or disease progression	Treatment-naïve patients (69)	63 (23-92) years	Male: 26(38) Female: 43 (62)
--	--	---------------------------------	-------------------------------	------------------	---------------------------------

The efficacy of RETEVMO in patients with advanced *RET* fusion-positive NSCLC was originally evaluated in a phase 1/2, multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001; see Table 14). Identification of a *RET* gene alteration was prospectively determined in local laboratories using next generation sequencing (NGS), polymerase chain reaction (PCR), or fluorescence *in situ* hybridization (FISH). Among *RET* fusion-positive NSCLC patients, the most common fusion partner was KIF5B, followed by CCDC6 and then NCOA4. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR), as determined by an independent review committee (IRC) according to RECIST v1.1.

In patients with *RET* fusion-positive NSCLC who were previously treated with platinum-based chemotherapy, 44% were White, 48% were Asian, 4.9% were Black, and 2.8% were Hispanic/Latino. ECOG performance status was 0-1 (97%) or 2 (3%), and 99% of patients had metastatic disease. Patients received a median of 2 prior systemic therapies (range: 1-15), and 58% of patients had prior anti-PD-1/PD-L1 therapy. At initial diagnosis, the majority of patients (90.7%) were diagnosed with nonsquamous NSCLC; one patient (0.4%) had squamous cell NSCLC; and the histology was unknown in 8.9% of patients. *RET* fusions were detected in 93.9% of patients using NGS (84.6% tumor samples, 9.3% blood or plasma samples); 4.0% using FISH; 1.6% using PCR; and 0.4% using nanostring technology.

In patients with *RET* fusion-positive NSCLC who were treatment-naïve, 70% were White, 19% were Asian, and 6% were Black. ECOG performance status was 0-1 (94%) or 2 (6%) and 99% of patients had metastatic disease. *RET* fusions were detected in 91.3% of patients using NGS (60.9% tumor samples, 30.4% blood or plasma samples); 7.2% using FISH; and 1.4 using PCR.

Efficacy results for patients with *RET* fusion-positive NSCLC previously treated with platinum chemotherapy are summarized in Table 15. A waterfall plot illustrating the best change in tumor size per RECIST v1.1 and based on independent review committee assessment is shown in Figure 1.


Table 15 - Efficacy Results in Patients with Metastatic *RET* Fusion-Positive NSCLC Previously Treated with Platinum Chemotherapy - LIBRETTO-001

	RETEVMO (n=247)
Overall Response Rate^a (95% CI)	62% (55%, 68%)
Complete response	8.1%
Partial response	53%
Duration of Response	
Median in months (95% CI)	31.6 (20, 42)

^a Confirmed overall response rate assessed by independent review committee.

CI=confidence interval; NE=not estimable.

Figure 1 - Waterfall Plot of Best Change in Tumor Burden in Patients with Metastatic *RET* Fusion-Positive NSCLC Previously Treated with Platinum Chemotherapy – LIBRETTO-001



Based on independent review committee assessment

Note: for each patient, the best change from baseline in the sum of diameters for all target lesions is represented by a vertical bar.

Baseline is defined as the last available measurement prior to the first dose of selpercatinib.

Note: Twenty-one patients not shown due to 16 patients having non-target lesions only, and 5 patients with no post-baseline target lesion measurement.

The efficacy of RETEVMO in patients with *RET* fusion-positive NSCLC of squamous histology has not been fully evaluated due to limited clinical data.

An exploratory subgroup analysis showed that, among the 144 patients who received an anti-PD-1 or anti-PD-L1 therapy, either sequentially or concurrently with platinum-based chemotherapy, the ORR was 64% (95% CI: 56%, 72%) and the median DOR was 27.7 months (95% CI: 17.4, NE).

Among the 247 patients with *RET* fusion-positive NSCLC, 16 had measurable central nervous system metastases at baseline as assessed by IRC. One patient received radiation therapy to the brain within 2 months prior to study entry. Responses in intracranial lesions were observed in 14 of these 16 patients; the median duration of response for patients with measurable central nervous system (CNS) disease at baseline was 10.1 months (95% CI: 7.4, 37.0).


Efficacy results for patients with treatment-naïve *RET* fusion-positive NSCLC are summarized in Table 16. A waterfall plot illustrating the best change in tumor size per RECIST v1.1 and based on independent review committee assessment is shown in Figure 2.

Table 16 - Efficacy Results in Patients with Treatment-Naïve Metastatic *RET* Fusion-Positive NSCLC - LIBRETTO-001

	RETEVMO (n=69)
Overall Response Rate^a (95% CI)	83% (72%, 91%)
Complete response	7%
Partial response	75%
Duration of Response	
Median in months (95% CI)	20.3 (15, 30)

^a Confirmed overall response rate assessed by independent review committee.

CI=confidence interval.

Figure 2 - Waterfall Plot of Best Change in Tumor Burden in Patients with Treatment-Naïve *RET* Fusion-Positive NSCLC - LIBRETTO-001

Based on independent review committee assessment

Note: for each patient, the best change from baseline in the sum of diameters for all target lesions is represented by a vertical bar.

Baseline is defined as the last available measurement prior to the first dose of selpercatinib.

LIBRETTO-431

Table 17 - Summary of Patient Demographics for Clinical Trials for the initial treatment of metastatic *RET* Fusion-Positive NSCLC – LIBRETTO-431

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex, n (%)
LIBRETTO-431	Randomized (1.6:1), open label, multicenter, Phase 3 study	<p>Patients received RETEVMO 160 mg orally twice daily continuously in 21-day cycles until unacceptable toxicity or disease progression</p> <p>OR</p> <p>Pemetrexed intravenously (IV) (500 mg per square meter of body-surface area) along with the investigator's choice of platinum therapy (carboplatin IV [AUC 5, maximum dose 750 mg] or cisplatin IV [75 mg per square meter]) with or without pembrolizumab IV (200 mg) every 21 days up to 35 cycles</p>	<p>RETEVMO arm: (n=129)</p> <p>Chemotherapy with pembrolizumab arm: (n=83)</p>	<p>59.8 (31-84) years</p> <p>60.2 (31-83) years</p>	<p>Male: 64 (49.6) Female: 65 (50.4)</p> <p>Male: 35 (42.2) Female: 48 (57.8)</p>

The efficacy of RETEVMO in patients with metastatic *RET* fusion-positive NSCLC was further evaluated in a phase 3, multicenter, open-label clinical trial (LIBRETTO-431; see Table 17). The study evaluated RETEVMO versus platinum-based and pemetrexed chemotherapy with or without pembrolizumab in patients with *RET* fusion-positive, unresectable locally advanced or metastatic NSCLC with no previous systemic therapy for metastatic disease. The demographics and efficacy results are presented for the intent-to-treat (ITT)-pembrolizumab population, which included patients who were stratified with the intent to receive pembrolizumab in the event of the control-arm assignment. Identification of a *RET* gene alteration was prospectively determined in local laboratories using NGS or PCR. Among patients with *RET* fusions, 60% were detected using NGS and 40% using PCR (89% in tumor samples; 11% in blood). The most common fusion partners were KIF5B (45% of patients) and CCDC6 (10% of patients).

Overall, in the ITT- pembrolizumab population, 41% of patients were White, 56% were Asian, and 1% were Black. ECOG performance status was 0-1 (97% of patients) or 2 (3% of patients), 68% of patients were never smokers, 93% of patients had metastatic disease at study entry, and 20% of patients had intracranial metastases at baseline, as determined by a neuroradiologic blinded independent central review (BICR). The majority of patients (98.1%) were diagnosed with lung adenocarcinoma.

The major efficacy outcome was progression-free survival (PFS) as determined by BICR according to RECIST v1.1. Efficacy results for LIBRETTO-431 for patients with metastatic *RET* fusion-positive NSCLC treated with selpercatinib are summarized in Table 18. At the time of this analysis, 19% of patients had died, and overall survival (OS) data were immature.

Table 18 - Efficacy Results for the Initial Treatment of Patients with Metastatic *RET* Fusion-Positive NSCLC - LIBRETTO-431

	Selpercatinib (n=129)	Chemotherapy with pembrolizumab (n=83)
PFS		
Number (%) of patients with an event	49 (38%)	49 (59%)
Median in months (95% CI)	24.8 (16.9, NE)	11.2 (8.8, 16.8)
Hazard ratio ^a (95% CI)	0.465 (0.309, 0.699)	
p-value ^b	0.0002	
Overall Response Rate		
ORR (95% CI)	84% (76, 90)	65% (54, 75)
Complete response	7%	6%
Partial response	77%	59%
Duration of Response		
Median in months ^c (95% CI)	24.2 (17.9, NE)	11.5 (9.7, 23.3)

Data from the pre-planned interim efficacy analysis.


^a Based on the stratified Cox proportional hazard model

^b Base on stratified log-rank test

^c Median duration of follow-up time; 18.0 months in the RETEVMO arm and 14.6 months in the chemotherapy with pembrolizumab arm.

CI=confidence interval; NE=not estimable.

Figure 3 Kaplan-Meier Curves of Progression-Free Survival in LIBRETTO-431: RETEVMO versus Chemotherapy with Pembrolizumab



Among the 212 randomized patients, 29 had measurable CNS metastases at baseline as assessed by BIRC. Responses in intracranial lesions were observed in 14 of 17 patients treated with RETEVMO and 7 of 12 patients treated with chemotherapy with pembrolizumab.

RET-Mutant Medullary Thyroid Cancer

LIBRETTO-001

Table 19 - Summary of Patient Demographics for Clinical Trials in Metastatic RET-Mutant Medullary Thyroid Cancer – LIBRETTO-001

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range) years	Sex, n (%)
LIBRETTO-001	Open label, multicenter, multi-cohort, Phase 1/2 study	Patients received RETEVMO 160 mg orally twice daily until unacceptable toxicity or disease progression	Patients previously treated with vandetanib or cabozantinib (or both) (152)	58 (17-90)	Male: 97 (64) Female: 55 (36)
			Vandetanib and cabozantinib treatment-naïve patients (143)	57 (15-87)	Male: 83 (58) Female: 60 (42)

The efficacy of RETEVMO in patients with *RET*-mutant MTC was originally evaluated in a phase 1/2, multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001; see Table 19). Identification of a *RET* gene alteration was prospectively determined in local laboratories using next generation sequencing (NGS), polymerase chain reaction (PCR), or fluorescence *in situ*

hybridization (FISH). Among *RET*-mutant MTC patients, the most common mutation was M918T, followed by extracellular cysteine mutation. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR), as determined by an independent review committee (IRC) according to RECIST v1.1.

In patients with *RET*-mutant MTC who were previously treated with vandetanib (78.9% of patients) or cabozantinib (54.6% of patients), 90% were White, 7% were Hispanic/Latino, 1.3% were Asian and 1.3% were Black. One pediatric patient was included (17 years of age). ECOG performance status was 0-1 (93%) or 2 (7%), and 98% of patients had metastatic disease. Patients received a median of 2 prior systemic therapies (range: 1-8). *RET* mutation status was detected in 80.3% of patients using NGS (77% tumor samples; 3.3% blood or plasma); 14.5% using PCR; and 5.3% using an unknown test. The protocol excluded patients with synonymous, frameshift, or nonsense *RET* mutations.

In patients with *RET*-mutant MTC who were vandetanib and cabozantinib treatment-naïve, 87% were White, 5.6% were Asian, 4.9% were Hispanic/Latino and 1.4% were Black. Two pediatric patients were included (ages 15 years and 16 years). ECOG performance status was 0-1 (96%) or 2 (4%) and 98% had metastatic disease. Nineteen percent (19%) of patients had received 1 or 2 prior systemic therapies (including 6.3% kinase inhibitors, 3.5% chemotherapy, 3.5% immunotherapy, 1.4% radioactive iodine, 0.7% mTOR inhibitor and 2.8% other systemic therapy). *RET* mutation status was detected in 80.4% of patients using NGS (74.8% tumor samples, 5.6% blood or plasma samples); 12.6% using PCR; and 7% using an unknown test.

Efficacy results for patients with metastatic *RET*-mutant MTC previously treated with vandetanib or cabozantinib are summarized in Table 20. A waterfall plot illustrating the best change in tumor size per RECIST v1.1 based on independent review committee assessment is shown in Figure 4.


Table 20 - Efficacy Results in Patients with Metastatic *RET*-Mutant MTC Previously Treated with Vandetanib or Cabozantinib - LIBRETTO-001

	RETEVMO (n=152)
Overall Response Rate^a (95% CI)	78% (70%, 84%)
Complete response	13%
Partial response	65%
Duration of Response	
Median in months (95% CI)	45.3 (34, NE)

^a Confirmed overall response rate assessed by independent review committee.

CI=confidence interval.

Figure 4 - Waterfall Plot of Best Change in Tumor Burden in Patients with Metastatic *RET*-Mutant MTC Previously Treated with Vandetanib or Cabozantinib - LIBRETTO-001



Based on independent review committee assessment

Note: Eligible patients are defined as treated patients. For each patient, the best change from baseline in the sum of diameters for all target lesions is represented by a vertical bar.

Baseline is defined as the last available measurement prior to the first dose of selpercatinib.

Note: Thirteen patients are not included because 7 patients have non-target lesion only, and 6 patients with no post-baseline target lesion measurement.

Efficacy results for patients with vandetanib and cabozantinib-naïve metastatic *RET*-mutant MTC are summarized in Table 21. A waterfall plot illustrating the best change in tumor size per RECIST v1.1 based on independent review committee assessment is shown in Figure 5.


Table 21 - Efficacy Results in Patients with Vandetanib and Cabozantinib-Naïve Metastatic *RET*-Mutant MTC - LIBRETTO-001

	RETEVMO (n=143)
Overall Response Rate^a (95% CI)	83% (75%, 88%)
Complete response	24%
Partial response	59%
Duration of Response	
Median in months (95% CI)	NE (51, NE)

^a Confirmed overall response rate assessed by independent review committee.

CI=confidence interval.

Figure 5 - Waterfall Plot of Best Change in Tumor Burden in Patients with Vandetanib and Cabozantinib-Naïve Metastatic *RET*-Mutant MTC Patients - LIBRETTO-001



Based on independent review committee assessment

Note: Eligible patients are defined as treated patients. For each patient, the best change from baseline in the sum of diameters for all target lesions is represented by a vertical bar.

Baseline is defined as the last available measurement prior to the first dose of selpercatinib.

Note: Ten patients are not included because 7 patients have non-target lesions only, and 3 patients with no postbaseline target lesions measurements.

LIBRETTO-531

Table 22 - Summary of Patient Demographics for Clinical Trials in Advanced or Metastatic, Kinase Inhibitor-Naïve, *RET*-Mutant MTC – LIBRETTO-531

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex, n (%)
LIBRETTO-531	Randomized (2:1), multicenter, open-label Phase 3 study	Patients received RETEVMO 160 mg orally twice daily OR	RETEVMO arm: (n= 193)	54 (12-79) years	Male: 115 (59.6) Female: 78 (40.4)
		Physician's choice of cabozantinib 140 mg once daily or vandetanib 300 mg orally once daily	cabozantinib or vandetanib arm: (n=98)	54 (18-84) years	Male: 68 (69.4) Female: 30 (30.6)
		Treatment in either arm continued until unacceptable toxicity or disease progression			

The efficacy of RETEVMO in patients with advanced or metastatic *RET*-mutant MTC was also evaluated in a phase 3 randomized (2:1), multicenter, open-label clinical trial (LIBRETTO-531; see Table 22). The study evaluated RETEVMO versus physician's choice of cabozantinib or vandetanib in patients with progressive, advanced kinase inhibitor-naïve, *RET*-mutant medullary thyroid cancer. Identification of a *RET* gene alteration was prospectively determined in local laboratories using NGS (in 90.4% of patients) and PCR (in 9.6% of patients). The most common mutation was M918T (62.5% of patients).

Overall, 69.4% of patients were White, 27.7% were Asian and 2.9% were Black. ECOG performance status at study entry was 0-1 for 98.3% of patients and 2 for 1.0% of patients. Distant metastasis was reported in 77.0% of patients at study entry. Only one adolescent patient was enrolled.

The major efficacy outcome measure was progression-free survival (PFS), as determined by a blinded independent review committee (BIRC) according to RECIST v1.1.

Efficacy results for LIBRETTO-531 based on the preplanned interim analysis are summarized in Table 23 and the Kaplan-Meier curve for PFS is shown in Figure 6. At the time of this analysis, the OS remains immature. A total of 18 patients (6.2%) had died, 8 deaths (4.1%) in the RETEVMO treated patients versus 10 deaths (10.2%) in patients treated with cabozantinib or vandetanib (HR=0.374, 95% CI: 0.147, 0.949).

Table 23 - Efficacy Results in Patients with Advanced or Metastatic Kinase Inhibitor-Naïve *RET*-Mutant MTC - LIBRETTO-531

	RETEVMO N=193	Cabozantinib or Vandetanib N=98
PFS		
Number (%) of patients with an event	26 (14%)	33 (34%)
Median in months (95% CI)	NE (NE, NE)	16.8 (12.2, 25.1)
Hazard ratio ^a (95% CI)	0.280 (95% CI: 0.165, 0.475)	
p-value ^b	<0.0001	
Overall Response Rate		
ORR (95% CI)	69% (62%, 76%)	39% (29%, 49%)
Complete response	12%	4%
Partial response	58%	35%
Duration of Response		
Median in months ^c (95% CI)	NE (NE, NE)	16.6 (10.4, NE)


Data from the pre-planned interim efficacy analysis.

^a Based on the stratified Cox proportional hazard model

^b Based on stratified log-rank test

^c Median duration of follow-up time; 11.1 months in the RETEVMO arm and 12.8 months in the chemotherapy with cabozantinib or vandetanib arm.

CI=confidence interval; NE=not estimable.

Figure 6: Kaplan-Meier Curves of Progression-Free Survival in LIBRETTO-531: RETEVMO versus Cabozantinib or Vandetanib

RET Fusion-Positive Thyroid Cancer**Table 24 - Summary of Patient Demographics for Clinical Trials in RET Fusion-Positive Thyroid Cancer – LIBRETTO-001**

Study #	Trial design	Dosage, route of administration and duration	Study subjects (n)	Mean age (Range)	Sex, n (%)
LIBRETTO-001	Open label, multicenter, multi-cohort, Phase 1/2 study	Patients received RETEVMO 160 mg orally twice daily until unacceptable toxicity or disease progression	Patients were radioactive iodine (RAI)-refractory (if RAI was an appropriate treatment option) (65)	59 (20-88) years	Male: 32 (49) Female: 33 (51)

The efficacy of RETEVMO in patients with *RET* fusion-positive thyroid cancer was evaluated in a phase 1/2, multicenter, open-label, multi-cohort clinical trial (LIBRETTO-001; see Table 24). Identification of a *RET* gene alteration was prospectively determined in local laboratories using next generation sequencing (NGS), polymerase chain reaction (PCR), or fluorescence *in situ* hybridization (FISH). For patients with *RET* fusion-positive thyroid cancers, CCDC6 was the most common fusion partner. The major efficacy outcome measures were overall response rate (ORR) and duration of response (DOR), as determined by an independent review committee (IRC) according to RECIST v1.1.

In patients with *RET* fusion-positive thyroid cancer, 65% were White, 20% were Asian, 11% were Hispanic/Latino, and 4.6% were Black. ECOG performance status was 0-1 (94%) or 2 (6%). All (100%) patients had metastatic disease with primary tumor histologies including papillary thyroid cancer (54 patients; 83%), poorly differentiated thyroid cancer (6 patients), anaplastic thyroid cancer (4 patients), or Hurthle cell thyroid cancer (1 patient). Patients were radioactive iodine (RAI)-refractory (if RAI was an appropriate treatment option) and had received a median of 2 prior therapies (range: 0-7). *RET* fusion-positive status was detected in 97% of patients using NGS (89.2% tumor samples, 7.7% blood or plasma samples); 1.5% using FISH; and 1.5% using FDM. Efficacy was evaluated in a cohort of patients (n=25) who were RAI-refractory and who had received sorafenib, lenvatinib, or both.


Efficacy results for patients with metastatic *RET* fusion-positive thyroid cancer who received prior systemic therapy are summarized in Table 25.

Table 25 - Efficacy Results in Patients with Metastatic *RET* Fusion-Positive Thyroid Cancer who Received Prior Systemic Therapy - LIBRETTO-001

	RETEVMO (n=41)
Overall Response Rate^a (95% CI)	85% (71%, 94%)
Complete response	12%
Partial response	73%
Duration of Response	
Median in months (95% CI)	26.7 (12, NE)

^a Confirmed overall response rate assessed by independent review committee.

CI=confidence interval; NE=not estimable.

Figure 7 - Waterfall Plot of Best Change in Tumor Burden in Patients with Metastatic *RET* Fusion-Positive Thyroid Cancer who received prior systemic therapy - LIBRETTO-001

Based on independent review committee assessment

Note: Eligible patients are defined as treated patients. For each patient, the best change from baseline in the sum of diameters for all target lesions is represented by a vertical bar.

Baseline is defined as the last available measurement prior to the first dose of selpercatinib.

14.2 Comparative Bioavailability Studies of the Product Monograph

An open-label, randomized, two-treatment, two-period, two-sequence, crossover, single dose (160 mg), adaptive designed oral comparative bioavailability study of RETEVMO tablets (1 × 160 mg) and RETEVMO capsules (2 × 80 mg) was conducted in 224 healthy, adult, male and female subjects under fasted conditions. A summary of the comparative bioavailability data from 191 subjects included in the statistical analysis is presented in the following table:

Table 26 - Summary Table of the Comparative Bioavailability Data

Selpercatinib (160 mg) Geometric Mean Arithmetic Mean (CV %)				
Parameter	Test^a	Reference^b	% Ratio of Geometric Means	94.12% Confidence Interval
AUC _T ^c (ng·h/mL)	18260.57 20814.51 (43.52)	20373.72 22231.43 (37.76)	89.6	83.7 – 95.9
AUC _T ^d (ng·h/mL)	19461.87 21524.70 (41.15)	20898.11 22638.00 (36.84)	93.1	88.4 – 98.1
C _{max} (ng·h/mL)	1363.99 1630.42 (43.37)	1514.45 1704.12 (39.52)	90.0	81.7 – 99.0
T _{max} ^e (h)	1.50 (0.75 – 36.00)	1.50 (0.75 – 36.02)		
T _{1/2} ^{c,f} (h)	16.28 (42.17)	16.17 (30.70)		

^a RETEVMO (selpercatinib) tablets, 160 mg (Eli Lilly Canada Inc.)

^b RETEVMO (selpercatinib) capsules, 80 mg (Eli Lilly Canada Inc.)

^c N=187

^d N=184

^e Expressed as the median (range) only

^f Expressed as the arithmetic mean (CV %) only

15 Microbiology

No microbiological information is required for this drug product.

16 Non-Clinical Toxicology

General Toxicology: Repeat-dose studies were conducted in rats and minipigs to characterize toxicity. Target organs of toxicity common to the rat and minipig were hematopoietic system, lymphoid tissues, tongue, pancreas, epiphyseal growth plate, and male reproductive tissues. In general, toxicities in these organs were reversible; the exception was the testicular toxicity. Reversible toxicity was observed in the ovaries and gastrointestinal tract in minipigs only; at high doses, gastrointestinal toxicity caused morbidity at exposures in minipigs that were generally lower than exposures determined in humans at the recommended dose. In one minipig study, females exhibited a slight, reversible increase in QTc prolongation of approximately 12% compared to controls and 7% compared to pre-dose values. Target organs of toxicity observed only in rats were incisor tooth, liver, vagina, lungs, Brunner's gland, and multi-tissue mineralization associated with hyperphosphatemia. These toxicities only occurring in these organs in rats were reversible.

In a 4-week general toxicology study, adolescent rats showed signs of physeal hypertrophy and tooth dysplasia at doses resulting in exposures \geq approximately 3 times the human exposure at the 160 mg twice daily clinical dose. In a 13-week general toxicity study,

adolescent minipigs showed signs of minimal to marked increases in physeal thickness at the 15 mg/kg high dose level (approximately 0.3 times the human exposure at the 160 mg twice daily clinical dose). Rats in both the 4- and 13-week toxicology studies had malocclusion and tooth discoloration at the high dose levels (≥ 1.5 times the human exposure at the 160 mg twice daily clinical dose) that persisted during the recovery period.

Carcinogenicity: In a 2-year rat study, vaginal tumors were observed in 5% of female rats at a dose of 40 mg/kg (approximately 1 times the clinical exposure by AUC at the 160 mg twice daily dose). No pre-neoplastic changes were observed in the reproductive tract of any of the female rats in the study. The clinical relevance of these findings is uncertain. In a 6-month transgenic RasH2 mouse study, Selpercatinib was not carcinogenic in male and female mice at doses of up to 60 mg/kg.

Genotoxicity: Selpercatinib was not mutagenic in the in vitro bacterial reverse mutation (Ames) assays, with or without metabolic activation, or clastogenic in the in vitro micronucleus assay in human peripheral lymphocytes, with or without metabolic activation. Selpercatinib was positive in the in vivo micronucleus assay in rats at concentrations >7 times the C_{max} at the human dose of 160 mg twice daily.

Reproductive and Development Toxicology: In general toxicology studies, male rats and minipigs exhibited testicular degeneration that was associated with luminal cell debris and/or reduced luminal sperm in the epididymis at selpercatinib exposures approximately 0.4 (rat) and 0.1 (minipig) times the clinical exposure by AUC at the recommended human dose of 160 mg twice daily. In a dedicated fertility study in male rats, administration of selpercatinib at doses up to 30 mg/kg/day (approximately twice the clinical exposure by AUC at the 160 twice-daily dose) for 28 days prior to cohabitation with untreated females did not affect mating or have clear effects on fertility. Males did, however, display a dose-dependent increase in testicular germ cell depletion and spermatid retention at doses ≥ 3 mg/kg (~ 0.2 times the clinical exposure by AUC at the 160 twice-daily dose) accompanied by altered sperm morphology at 30 mg/kg.

In a dedicated fertility study in female rats treated with selpercatinib for 15 days before mating to Gestational Day 7, there were decreases in the number of estrous cycles at a dose of 75 mg/kg (approximately equal to the human exposure by AUC at the 160 mg twice-daily clinical dose). Although selpercatinib did not have clear effects on mating performance or ability to become pregnant at any dose level, half of females at the 75 mg/kg dose level had 100% nonviable embryos. At the same dose level in females with some viable embryos, there were increases in post-implantation loss.

Selpercatinib administration to pregnant rats during the period of organogenesis at oral doses ≥ 100 mg/kg [approximately 3.6 times the human exposure based on the area under the curve (AUC) at the clinical dose of 160 mg twice daily] resulted in 100% post-implantation loss. At the dose of 50 mg/kg [approximately equal to the human exposure (AUC) at the clinical dose of 160 mg twice daily], 6 of 8 females had 100% early resorptions; the remaining 2 females had high levels of early resorptions with only 3 viable fetuses across the 2 litters. All viable fetuses had decreased fetal body weight and malformations (2 with short tail and one with small snout and localized edema of the neck and thorax).

In the general toxicology study in minipigs, there were findings of decreased or absent corpora lutea at a selpercatinib dose of 15 mg/kg (approximately 0.3 times the human exposure by AUC at the 160 mg twice-daily clinical dose). Corpora luteal cysts were present in the minipig at selpercatinib doses ≥ 2 mg/kg (approximately 0.07 times the human exposure by AUC at the 160 mg twice-daily clinical dose).

Juvenile Toxicity: In a study in juvenile rats, epiphyseal growth plate changes similar to those

in adolescent rats were observed. These changes were associated with decreased femur length and reductions in bone mineral density, and were not reversible.

Large intestinal enteropathy was characterized by increased basophilia and occasional vacuolation of the crypt epithelium.

In juvenile male rats administered selpercatinib as juveniles and mated as adolescents with untreated female rats, the following effects on reproductive performance were observed: lower male fertility and copulation indices, increased pre-implantation loss, increased post-implantation loss, and lower mean number and proportion of viable embryos.

Patient Medication Information**READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE****PrRETEVMO®****Selpercatinib capsules****Selpercatinib tablets**

This patient medication information is written for the person who will be taking **RETEVMO**. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This patient medication information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about RETEVMO, talk to a healthcare professional.

Serious Warnings and Precautions

- Only a healthcare professional who has experience treating cancer should treat you with this drug.
- RETEVMO can harm your unborn baby.
- RETEVMO can cause serious side effects including:
 - **Hemorrhage** (severe bleeding; blood loss): Bleeding can occur with RETEVMO treatment and can be serious. It may even cause death. If you experience bleeding, your healthcare professional may stop your treatment.
 - **Liver problems:** Liver problems and increased liver enzymes are very common with RETEVMO and may sometimes be serious. Your healthcare professional will run blood tests to check your liver before and during treatment.
 - **Allergic reactions:** RETEVMO may cause a fever, rash, muscle or joint pain. This is common in the first month of treatment. If you experience an allergic reaction, your healthcare professional may prescribe medicine to treat your reaction.
 - **Hypertension** (high blood pressure): High blood pressure is very common with RETEVMO and may sometimes be serious. Your blood pressure should be well controlled before you start taking RETEVMO. Your healthcare professional should check your blood pressure regularly when you take RETEVMO. If blood pressure becomes a problem, your healthcare professional may prescribe medicine to treat your high blood pressure.
 - **Interstitial Lung Disease/pneumonitis** (inflammation in the lungs): Inflammation in the lungs can occur with RETEVMO treatment which can be serious, and may cause death. Your healthcare professional may stop your treatment as necessary.
 - **QT prolongation** (a heart rhythm condition): Changes to your heart rhythm can occur with RETEVMO treatment and can be serious. Your healthcare professional will check that your heart is working properly before and during your treatment.

See the Serious side effects and what to do about them table, below, for more information on these serious side effects.

What RETEVMO is used for:

See the following boxed text:

For the following indications, RETEVMO has been approved with conditions (NOC/c). This means it has passed Health Canada's review and can be bought and sold in Canada, but the manufacturer has agreed to complete more studies to make sure the drug works the way it should. For more information, talk to your healthcare professional.

RETEVMO is used to treat certain cancers caused by abnormal *RET* genes in:

- adults with a type of lung cancer called non-small cell lung cancer (NSCLC). It is used when your cancer has spread to other parts of your body.
- adults and children 12 to 17 years old with medullary thyroid cancer. It is used when:
 - your cancer is advanced or has spread to other parts of your body, and
 - your cancer cannot be removed using surgery
- adults with differentiated thyroid cancer. It is used when:
 - your cancer is advanced or has spread to other parts of your body,
 - your cancer cannot be removed using surgery,
 - radioactive iodine therapy did not work, is no longer working or is not appropriate, and
 - you have tried treatment with sorafenib and/or lenvatinib

Your healthcare professional will perform a test to make sure that RETEVMO is right for you.

What is a Notice of Compliance with Conditions (NOC/c)?

A Notice of Compliance with Conditions (NOC/c) is a type of approval to sell a drug in Canada.

Health Canada only gives an NOC/c to a drug that treats, prevents, or helps identify a serious or life-threatening illness. The drug must show promising proof that it works well, is of high quality, and is reasonably safe. Also, the drug must either respond to a serious medical need in Canada or be much safer than existing treatments.

Drug makers must agree in writing to clearly state on the label that the drug was given an NOC/c, to complete more testing to make sure the drug works the way it should, to actively monitor the drug's performance after it has been sold, and to report their findings to Health Canada.

How RETEVMO works:

RETEVMO works by blocking the action of RET protein kinase. Specific RET altered proteins can lead to uncontrolled cell growth and cancer. RETEVMO stops specific RET altered proteins from working. RETEVMO may slow or stop the cancer from growing. It may also help to shrink the cancer.

The ingredients in RETEVMO are:

Medicinal ingredients: selpercatinib

Capsule Non-medicinal ingredients: Black iron oxide, colloidal silicon dioxide, FD & C Blue No. 1 (80 mg capsule only), gelatin, microcrystalline cellulose, pharmaceutical grade printing ink, titanium dioxide

Tablet Non-medicinal ingredients: Croscarmellose sodium, hydroxypropyl cellulose, mannitol, microcrystalline cellulose, and sodium stearyl fumarate. The tablet film coating material contains ferrousferrous oxide, polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. Additionally, the film coating of the 80 mg tablets contain ferric oxide.

RETEVMO comes in the following dosage forms:

Capsules: 40 mg and 80 mg

Tablets: 40 mg and 80 mg

Do not use RETEVMO if:

- You are allergic to selpercatinib or any of the other ingredients in this medicine.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take RETEVMO. Talk about any health conditions or problems you may have, including if you have:

- heart problems or have a family history of heart problems, including a condition known as QT prolongation. QT prolongation happens when there are changes in the electrical activity of the heart. This can cause heart rhythm problems.
- high blood pressure
- liver problems
- kidney problems
- diabetes
- a recent history of significant bleeding
- lung or breathing problems other than lung cancer
- a history of stroke or brain injury
- a history of anorexia or other eating disorder
- persistent vomiting
- been told that you have an imbalance of electrolytes in your blood, such as potassium, magnesium or calcium
- a condition called “autonomic neuropathy” that causes problems with blood pressure, heart rate, sweating, bowel and bladder control and digestion

Other warnings you should know about:

- **Risk of wound healing problems:** Wounds may not heal properly during treatment with RETEVMO. Tell your healthcare professional if you plan to have any surgery before or during treatment with RETEVMO.
 - You should stop taking RETEVMO at least 7 days before planned surgery.

- Your healthcare professional should tell you when you may start taking RETEVMO again after surgery.
- **Tumor lysis syndrome:** RETEVMO can cause a serious side effect known as Tumor lysis syndrome (TLS). TLS is caused by a sudden, rapid death or breakdown of cancer cells due to treatment. TLS is a condition that can cause kidney failure and abnormal heart rhythm. You may be at risk of TLS if you have:
 - Tumors that are growing quickly,
 - Many or large tumors,
 - Problems with your kidneys or
 - You do not have enough water or fluids in your body.

Your healthcare professional will check you for signs and symptoms of TLS. Drink plenty of water when taking RETEVMO to stay well hydrated.

- **Pregnancy and breastfeeding:**

Female patients:

- If you are pregnant, able to get pregnant or think you are pregnant, there are specific risks you should discuss with your healthcare professional.
- You should not take RETEVMO if you are pregnant. It can harm your unborn baby.
- If you are able to become pregnant:
 - Your healthcare professional will do a pregnancy test before you start RETEVMO. This test must show that you are not pregnant.
 - Avoid becoming pregnant while you are taking RETEVMO. Use highly effective birth control during treatment and for at least 2 weeks after your last dose. Talk to your healthcare professional about birth control methods that may be right for you during this time.
 - Tell your healthcare professional right away if you become pregnant or think you are pregnant during treatment with RETEVMO.
- If you are breastfeeding or planning to breastfeed: it is not known if RETEVMO passes into breast milk. Do not breastfeed during treatment with RETEVMO and for at least 2 weeks after your final dose. Talk to your healthcare professional about the best way to feed your baby during this time.
- **Male patients with female partners who are able to become pregnant:**
 - Use highly effective birth control while you are on RETEVMO and for at least 2 weeks after your last dose.
 - If during your treatment with RETEVMO, your sexual partner becomes pregnant or thinks she may be pregnant, tell your healthcare professional right away.
- **Fertility:** Taking RETEVMO may affect fertility in males and females. This means that it may be difficult for you to have a child. Talk to your healthcare professional if you have questions about this.

- **Driving and Using Machines:** Fatigue and dizziness can occur with RETEVMO. Be cautious after taking RETEVMO to see how you feel before driving a vehicle or using machinery.
- **Children and adolescents:**
 - RETEVMO is not approved for the treatment of lung cancer or thyroid cancer other than medullary thyroid cancer in patients under 18 years of age.
 - For the treatment of medullary thyroid cancer, RETEVMO is not approved for use in children under 12 years of age.
 - Taking RETEVMO may cause slowed growth in children 12 to 17 years of age.
 - Taking RETEVMO may cause **Slipped Capital Femoral Epiphysis/Slipped Upper Femoral Epiphysis** (SCFE/SUFE, hip joint damage in children 12 to 17 years of age). The healthcare professional will check for symptoms and treat as needed. See the “**Serious side effects and what to do about them**” table, below, for more information on these and other serious side effects.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with RETEVMO:

- Alfentanil – used to treat pain
- Amphotericin B – used to treat fungal infections
- Avanafil – used to treat erectile dysfunction
- Bosentan, diltiazem, verapamil – used to treat high blood pressure and heart arrhythmias
- Buprenorphine – used to treat pain and help people stop taking pain medication
- Bupropion – used to treat depression and to help people stop smoking
- Buspirone – used to treat anxiety
- Carbamazepine – used to treat seizures, nerve pain, and sometimes used to treat bipolar disorders
- Ciprofloxacin, clarithromycin – used to treat bacterial infections
- Conivaptan – used to treat low sodium levels in the blood
- Dabigatran – used to prevent blood clots
- Darifenacin – used to treat a frequent need to urinate
- Darunavir, efavirenz, ritonavir, tipranavir – used to treat human immunodeficiency virus (HIV) infection
- Dexamethasone and other corticosteroids – used to treat asthma, severe allergies, certain lung diseases, a number of skin diseases, brain and eye swelling, and certain forms of arthritis. Dexamethasone may also be used to treat certain types of cancers.
- Dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole, cimetidine, famotidine, nizatidine, aluminum hydroxide gel, subsalicylate, calcium carbonate, magnesium hydroxide, ranitidine – used to treat too much stomach acid
- Enzalutamide – used to treat prostate cancer

- Everolimus – used to treat cancer
- Fluconazole, itraconazole, ketoconazole, miconazole, posaconazole, voriconazole, rifampin, rifabutin – used to treat fungal and bacterial infections
- Ibrutinib – used to treat cancer
- Lomitapide, lovastatin, simvastatin – used to treat high cholesterol
- Midazolam – used for sedation and to treat anxiety
- Montelukast – used to treat asthma
- Naloxegol – used to treat constipation caused by some pain medications
- Paclitaxel – used to treat a number of different cancers
- Phenobarbital, phenytoin – used to prevent and control seizures
- Repaglinide, rosiglitazone, pioglitazone – used to treat diabetes
- Sorafenib – used to treat cancer
- Selexipag – used to treat pulmonary arterial hypertension
- St. John's Wort – an herbal medicine used to treat depression
- Telithromycin – used to treat certain types of bacterial infection
- Triazolam – used to help with sleeping
- Vardenafil – used to treat erectile dysfunction
- Medicines that cause heart rhythm conditions, including QT prolongation or torsade de pointes
- Medicines that cause a decrease in electrolyte levels. This includes:
 - diuretics (used to remove water from the body)
 - laxatives (used to loosen stools and increase bowel movements)
 - enemas (used to empty the bowels)
- Medicines that cause a decrease in heart rate. This includes:
 - beta-blockers (used to lower blood pressure)
 - digitalis glycosides (such as digoxin; used to treat congestive heart failure and abnormal heart rhythms)
 - calcium channel blockers (such as diltiazem and verapamil; used to lower blood pressure)
 - cholinesterase inhibitors (used to treat Alzheimer's and dementia symptoms)
 - alpha2-adrenoceptor agonists (used to treat high blood pressure, irregular heart rate, sedation, and the inability to feel pain)
 - I_f inhibitors (used to treat heart failure)
 - sphingosine-1 phosphate receptor modulators (used to treat multiple sclerosis)
- Products with grapefruit

Ask your healthcare professional if you are not sure whether your medicine is one of the medicines listed above.

How to take RETEVMO:

- Take exactly as prescribed for you by your healthcare professional. Do not change your dose or stop taking RETEVMO unless your healthcare professional tells you to. Check with your healthcare professional if you are not sure.
- RETEVMO is taken twice a day. Take at about the same time every day, about 12 hours apart.
- Swallow RETEVMO whole. Do not crush or chew the capsule or tablet.
- Take with or without food, unless you are also taking a proton pump inhibitor (see next bullet point).
- During treatment with RETEVMO, you should avoid taking medicines to treat stomach-acid issues called proton pump inhibitors, H2 blockers and antacids. These medicines can affect how RETEVMO works. If this cannot be avoided and you need to take:
 - a proton pump inhibitor (such as dexlansoprazole, esomeprazole, lansoprazole, omeprazole, pantoprazole sodium, and rabeprazole): then, take RETEVMO with food.
 - an H2 blocker (such as famotidine, nizatidine, and cimetidine): then, take RETEVMO 2 hours before or 10 hours after the H2 blocker.
 - an antacid (such as calcium carbonate, magnesium hydroxide, and simethicone): then, take RETEVMO 2 hours before or 2 hours after taking the antacid.

Usual dose:

The usual dose depends on your body weight. Your healthcare professional will determine the right dose for you.

- For patients weighing less than 50 kg, the usual dose is: 120 mg twice a day. This is a total daily dose of 240 mg.
- For patients weighing 50 kg or greater, the usual dose is: 160 mg twice a day. This is a total dose of 320 mg.

Your healthcare professional may interrupt, change, or stop your dose. This may occur:

- based on your current health,
- if you take certain other medications,
- if your disease gets worse,
- if you develop certain side effects, or
- you are having surgery.

Overdose:

If you think you, or a person you are caring for, have taken too much RETEVMO, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed Dose:

- If you miss a dose and it is more than 6 hours until your next scheduled dose, take the missed dose as soon as you remember. Then continue with your next dose at your regular time.
- If it is within 6 hours of your next dose, skip the missed dose. Wait and take your next dose at your scheduled time. Do not take an extra dose.
- If you vomit after taking a dose, do not take an extra dose. Take your next dose at your regular time.

Possible side effects from using RETEVMO:

These are not all the possible side effects you may have when taking RETEVMO. If you experience any side effects not listed here, tell your healthcare professional.

- Dry mouth, diarrhea, constipation, nausea, abdominal pain, vomiting
- Swelling in the stomach, arms, legs, hands, feet, eyes, face or other parts of your body
- Difficulty emptying your bladder, involuntary leakage of urine
- Fatigue, tiredness
- Decreased appetite
- Body pain, bone pain
- Headache, dizziness, ringing in the ears
- Cough, difficulty swallowing, shortness of breath
- Runny and stuffed nose, itchy eyes, sneezing, flushed and hot skin
- Skin rash, dry skin, skin sores or open wounds
- Confusion
- Erectile dysfunction
- Muscle pain, stiffness, weakness, cramps, joint swelling, neck pain.
- Feeling anxious, sad mood, difficulty sleeping, decreased sexual desire

RETEVMO can cause abnormal ECG and blood test results. ECG stands for electrocardiogram. Your healthcare professional will do some tests before and during your treatment. These include checking for heart and liver problems, thyroid function and electrolyte levels in your blood. The healthcare professional will interpret the results. They will tell you if there are any abnormalities in your tests that might need treatment.

Serious side effects and what to do about them

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Stop taking this drug and get immediate medical help
	Only if severe	In all cases	
Very Common			
Hemorrhage (severe bleeding; blood loss): very low blood pressure, rapid heart rate, cold		✓	

clammy skin, weakened pulse, fatigue, tingling or numbness in arms or legs, changes to vision, changes to balance, fainting, sudden severe headache, difficulty speaking, nausea, vomiting.			
Hypertension (high blood pressure): headache, nosebleeds, shortness of breath, dizziness, chest pain, confusion.		✓	
Hypothyroidism (low levels of thyroid hormone): fatigue, increased sensitivity to cold, constipation, dry skin, weight gain.		✓	
Leukopenia, neutropenia, lymphopenia (low white blood cells): chills, fever, infection. fatigue, aches and pains, and flu-like symptoms.		✓	
Liver problems and increased liver enzymes: loss of appetite, feeling sick or being sick, yellow skin, itching or pain in your liver area, yellowing of your skin and/or the white part of your eyes (jaundice), dark “tea-colored” urine, sleepiness, bleeding or bruising, loss of appetite, nausea or vomiting, pain on the upper right side of stomach.		✓	
QT Prolongation (a heart rhythm condition): a change in the way your heart beats (palpitations), dizziness, shortness of breath, chest pain, fainting, loss of consciousness, seizures.		✓	
Thrombocytopenia (low blood platelets): bruising or bleeding for longer than usual if you hurt yourself, tiredness, weakness, vomiting blood or if your vomit looks like coffee grounds, pink or brown urine, red or black (looks like tar) stools, coughing up blood or blood clots, unusual bleeding or bruising of your skin, menstrual		✓	

bleeding that is heavier than normal, unusual vaginal bleeding, nose bleeds that happen often, drowsiness or difficulty being awakened, confusion, headache, change in speech.			
Urinary tract infections: pain or burning sensation when peeing, need to pee more often than usual, pee that looks cloudy, blood in pee, feeling hot and shivery, pain in the lower stomach and back.		✓	
Common			
Allergic reactions: fever, rash, muscle or joint pain.			✓
Anemia (low red blood cells): Being short of breath, feeling very tired, loss of energy, weakness, chest pain, headache, dizziness, feeling light-headed.		✓	
Chylothorax (build-up of chyle (lymphatic fluid) in the space around the lung): shortness of breath, cough, chest discomfort, or trouble breathing.		✓	
Eye problems: dry eye, eye swelling, blurry vision.		✓	
Heart problems, including: <ul style="list-style-type: none"> • Chest discomfort or pain • Cardiac arrhythmias/ palpitations: fast, slow or irregular heartbeat, heart racing, skipping beats, shortness of breath, weakness, inability to exercise, fluid in the legs. • Pericardial effusion (fluid around the heart): sharp, piercing chest pain over the centre or left side of the chest, which is more intense when breathing in, shortness of breath, palpitations, fever, fatigue, weakness or feeling sick, cough, swelling in the abdomen or leg. 			✓

<ul style="list-style-type: none"> • Cardiac arrest (heart stops beating): sudden collapse, no pulse, no breathing, loss of consciousness. 			
<p>Hyperthyroidism (overactive thyroid gland): weight loss, rapid or irregular heartbeat, increased appetite, anxiety.</p>		✓	
<p>Infections, including of the eye, nose, tooth, mouth, sinuses, throat, lungs, air passages, skin, stomach, intestines, blood: Fever and chills, fast heartbeat, nausea and vomiting, diarrhea, fatigue or weakness, discolored skin, sweating, severe pain, cough, shortness of breath, sharp chest pain, and rapid breathing.</p>		✓	
<p>Nervous system disorders: amnesia, decreased attention, memory problems, decreased sense of taste, numbness, burning sensation, feeling light-headed, fainting, seizure, tremor.</p>		✓	
<p>Respiratory (breathing) disorders, including:</p> <ul style="list-style-type: none"> • Pleural effusion (fluid around your lungs) • Interstitial Lung Disease/Pneumonitis (inflammation of the lung tissue) • Pulmonary embolism (blood clot in the lungs) • Respiratory failure (stop breathing) <p>Symptoms include: changes in your voice, shortness of breath, chest pain, nose bleed, coughing up blood, nasal congestion and dryness, cough, sore throat, pain in ear, runny nose, bluish color around skin of fingernails and lips.</p>		✓	
<p>Skin disorders: acne, hair loss, dry or flaky skin, itching, rash, reddening of the skin, extra sensitivity to the sun, excessive</p>		✓	

sweating, redness or swelling on the palms of the hands and soles of the feet.			
Slipped Capital Femoral Epiphysis/Slipped Upper Femoral Epiphysis (SCFE/SUFE, hip joint damage in children 12 to 17 years of age): pain in the groin, hip, thigh (upper leg) and/or knee; change in the way you walk (limp), leg stiffness, harder to rotate a leg.		✓	
Less Common			
Embolism (blockage in a blood vessel): Sudden shortness of breath, chest pain, coughing up blood, fainting, falling down, changes to your eyesight, numbness and tingling in your arms or legs, rapid breathing, rapid heart rate, muscle weakness.			✓
Gastrointestinal disorders: stomach pain, diarrhea often with blood, rectal bleeding and pain, weight loss, fatigue, nausea, vomiting, fever, difficulty swallowing, sore throat, cough, chest pain, pain in gums, mouth sores.		✓	
Hypotension (low blood pressure): dizziness, fainting, light-headedness, blurred vision, nausea, vomiting, fatigue (may occur when you go from lying or sitting to standing up).		✓	
Kidney failure/Acute kidney injury: Pee less, swelling in your legs, ankles or feet, short of breath, chest pain, muscle cramps, confusion, nausea, weakness, skin rashes, irregular heartbeat.			✓
Tumor lysis syndrome (the sudden, rapid death or breakdown of cancer cells due to treatment): nausea, shortness of breath,			✓

irregular heartbeat, heart rhythm disturbances, pee less, cloudy pee, muscle spasms or twitching, tiredness, joint pain, severe muscle weakness, seizures.			
--	--	--	--

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/drug-device-reporting>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Store RETEVMO at room temperature (15°C to 30°C).
- Do not use this medicine after the expiry date (EXP) shown on the bottle.
- Keep out of reach and sight of children.

If you want more information about RETEVMO:

- Talk to your healthcare professional.
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website www.lilly.ca, or by calling 1-888-545-5972.

This leaflet was prepared by Eli Lilly Canada Inc.

Date of Authorization: 2026-02-18

RETEVMO is a registered trademark owned by or licensed to Eli Lilly and Company, its subsidiaries or affiliates.

B3.0-RET-0010-CA-PM-YYYYMMDD